



AJOONI BIOTECH LIMITED



ANNUAL REPORT 2020-21

Name of the Company	AJOONI BIOTECH LIMITED												
Corporate Identification Number (CIN)	L85190PB2010PLC040162												
Directors	<table> <tr> <td>Mr. Jasjot Singh</td> <td>- Managing Director</td> </tr> <tr> <td>Mr. Partek Singh</td> <td>- Director</td> </tr> <tr> <td>Mr. Gursimran Singh</td> <td>- Director</td> </tr> <tr> <td>Mr. Ramandeep Singh</td> <td>- Independent Director</td> </tr> <tr> <td>Mr. Imtेशwar Singh</td> <td>- Independent Director</td> </tr> <tr> <td>Ms. Simmi Chabbra</td> <td>- Independent Woman Director</td> </tr> </table>	Mr. Jasjot Singh	- Managing Director	Mr. Partek Singh	- Director	Mr. Gursimran Singh	- Director	Mr. Ramandeep Singh	- Independent Director	Mr. Imtेशwar Singh	- Independent Director	Ms. Simmi Chabbra	- Independent Woman Director
Mr. Jasjot Singh	- Managing Director												
Mr. Partek Singh	- Director												
Mr. Gursimran Singh	- Director												
Mr. Ramandeep Singh	- Independent Director												
Mr. Imtेशwar Singh	- Independent Director												
Ms. Simmi Chabbra	- Independent Woman Director												
Chief Financial Officer	Mr. Gurmeet Singh (till 14/ 08/ 2021)												
Chief Financial Officer	Mr. Jasjot Singh (w.e.f.14/ 08/ 2021)												
Company Secretary	Ms. Swati Vijan (ACS-39179)												
Auditors	M/s Harjeet Parvesh & Co.,Chartered Accountant, Mohali (FRN: 017437N)												
Secretarial Auditor	M/s. M.R. CHECHI & ASSOCIATES, Practicing Company Secretary Chandigarh												
Registered Office /Corporate office	D-118, Industrial Area, Phase – VII, Mohali-160055												
Factory	Gaib Di Pulli, Village Bullepur, Tehsil Khanna, Distt. Ludhiana, Punjab-141401												
Registrar and Share Transfer Agent	Cameo Corporate Services Ltd Subramanian Building No 1, Club House Road, Chennai - 600 002												
Banker	Canara Bank, SCO: 56, Chandi Path, Sector 30-C, Chandigarh-160030 HDFC Bank Limited, G T Road, Khanna, Punjab-141401												

Disclaimer

In this Annual Report, we have disclosed forward looking information to help our investors comprehend our prospectus and take informed investment decisions. This report is based on certain forward looking statements that we periodically make to anticipate results based on the management's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should know or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated or estimated projected. We undertake no obligation to publicly update any forward looking statements, whether as a results of new information, future events or otherwise.

AJOONI BIOTECH LIMITED
11th Annual Report- 2020-2021



FROM THE DESK OF THE CHAIRMAN
Mr. Jasjot Singh, Chairman cum Managing Director

Dear Shareholders,

I hope you and your families are safe and healthy.

I am delighted to share with you the events and developments of your Company during the course of the financial year 2020-21.

Financial Year 2020-21 was one of the toughest years due to the COVID-19 pandemic and has led to many challenges. With a nation-wide lockdown at the beginning of the year, your company quickly adapted to this situation and immediately approached the state government to declare animal feed as an essential commodity and its plant became operational within a week's time of lockdown after obtaining all regulatory approvals and during the entire lockdown period we managed to maintain the supply chain & other logistics uninterrupted to the satisfaction of our customers and suppliers while adoption of all health protocol announced by the government.

The year gone-by was representative of the value created for all its stakeholders. Business growth through competitively growing your Company's core business of Animal Feed by entering into long term agreements /association with leading MNC engaged in the business of dairy and animal health care products.

A new modern plant of Feed is setup and commenced commercial production in spite of adverse business environment due to pandemic. The focus on R&D continues with the setting up a new state-of-the-art R&D facility at Plant site which will help us in improving our product quality and cost optimising in long run. Best human resources are engaged to offer best product and services to our customers.

The fiscal year 2020-21 was an excellent year for Ajooni Biotech Ltd in terms of business growth. The turnover has increased 21.56 % and profit before tax for the year representing year-on-year growth of 4.7 %.

The business is doing well with new product launches and expanding its customer base. Your Company believes in inclusive growth that aims at enhancing the competitiveness of the businesses while simultaneously advancing the economic and social conditions of the communities in which it operates.

We believe that there is a good potential for Feed Supplement business. Looking at this opportunity, we started efforts to develop new and unique animal health care products and I am confident that this new business will generate good profits and create overall value to all the Stakeholders.

We are confident of achieving our long term objectives of inclusive, sustainable and profitable growth. As we look ahead, I feel confident of strong growth in the medium to long term which will enable us to improve our performance further and create greater shareholder value.

I would like to take this opportunity to thank all our employees for their contribution in the continued success of Ajooni.

I would also like to extend my gratitude towards our business partners, associates, vendors and also the bankers and government agencies for their continued support.

I would also like to express my sincere appreciation to all of our Shareholders for their faith, trust, encouragement and support.

Yours sincerely,

Jasjot Singh

Chairman cum Managing Director

CONTENTS

S.NO.	PARTICULARS	PAGE NO.
1	Notice of AGM along with Explanatory Statement	01
2	Directors' Report for F.Y. 2020-21	18
3	Form MGT-9- (Extract of Annual Return)	28
4	Form AOC-2 (Disclosure for contracts/ arrangements with related parties	38
5	Particulars Of Employees As Per Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014	39
6	Corporate Governance Report	40
7	Management Discussion & Analysis Report	56
8	Conservation Of Energy, Technology Absorption, Foreign Exchange Earnings And Outgo	58
9	Form MR-3- Secretarial Audit Report	59
10	Disclosures to Annual report	62
11	Independent Auditor's Report	64
12	Balance Sheet	69
13	Statement of Profit & Loss	70
14	Cash Flow Statement	71
15	Notes to the Financial Statements	73
16	Significant Accounting Policies	79

AJOONI BIOTECH LIMITED

Registered office: D-118, Industrial Area, Phase VII, Mohali, Punjab 160055 India
CIN:L85190PB2010PLC040162,E-mail: ajooni118@gmail.com, Website: <https://ajoonibiotech.com/>

=====

NOTICE OF 11TH ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT THE 11TH ANNUAL GENERAL MEETING ('AGM') OF THE SHAREHOLDERS OF AJOONI BIOTECH LIMITED ('THE COMPANY') WILL BE HELD ON MONDAY, 27TH DAY OF SEPTEMBER, 2021, AT 10.30 A.M. THROUGH VIDEO CONFERENCING ('VC')/ OTHER AUDIO VISUAL MEANS (OAVM) FACILITY TO TRANSACT THE FOLLOWING BUSINESS:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2021, together with the Reports of the Board of Directors and Auditors thereon.
2. To re-appoint a Director in place of Mr. Gursimran Singh (DIN: 02209675) Director, who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:**3. TO CONSIDER AND TAKE APPROVAL FOR RELATED PARTY TRANSACTIONS**

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 188 of the Companies Act, 2013 ("Act") and other applicable provisions, if any, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, as amended till date, and subject to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), if applicable and the Company's policy on Related Party transaction(s), approval of Shareholders be and is hereby accorded to the Board of Directors of the Company to enter into contract(s)/ arrangement(s)/ transaction(s) with the related party within the meaning of Section 2(76) of the Act and Regulation 2(1)(zb) of the Listing Regulations, for purchase or supply of goods or materials, leasing of property of any kind, availing or rendering of any services, appointment of agent for purchase or sale of goods, materials services or property or appointment of such parties to any office or place of profit in the company, or its subsidiary or associate company or any other transactions of whatever nature which should not exceed Rs. 75 crores (Rupees Seventy Five Crore Only) which will be carried out at arm's length basis and in the ordinary course of business of the Company."

"RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the Company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution."

4. TO TAKE APPROVAL UNDER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013 TO SELL, LEASE OR OTHERWISE DISPOSE OFF, TO MORTGAGE/ CREATE CHARGES ON THE PROPERTIES OF THE COMPANY AND IN THIS REGARD

To consider and if thought fit, to pass, the following resolution as a **Special Resolution**:

“RESOLVED THAT in supersession of all the earlier resolutions passed and pursuant to the provisions of Section 180(1)(a) of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013, and the rules made thereunder, including any statutory modification or re-enactment thereof, for the time being in force (the “Act”), and such other approvals/sanctions/permissions as may be necessary, the consent of the members of the Company be and is hereby accorded, to the Board of Directors of the Company (hereinafter referred to as the “Board” which term shall be deemed to include any committee(s) constituted/ to be constituted by the Board to exercise its powers including the powers conferred by this resolution and with the power to delegate authority to any person or persons) to sell, lease or otherwise dispose of, to mortgage, charge, hypothecate, pledge or otherwise, encumber from time to time, movable and/or immovable, tangible and/or intangible properties/assets, both present and future and/or whole or substantially the whole of the undertaking(s) of the Company in such form, manner and time as the Board may deem fit, for securing any loans and/or borrowings and/or advances and/or guarantees and/or any financial assistance whether all/any of such financial assistance taken or to be taken in foreign currency and/or rupee currency by the Company and/or affiliates/associates Companies from any lender including without limitation, any bank, financial or other institutions, non resident Indians, foreign institutional investors and/or public financial institutions as defined under Section 2(72) of the Act and/ or any other persons, bodies corporate and/or eligible foreign lenders and/or any entity/entities, machinery suppliers and/or any other person(s) or institution(s) providing finance for purchase of assets/business of the Company or for working capital or for purchase of specific items of machinery and equipment under any deferred payment scheme or bills discounting/rediscounting scheme or in favour of trustees for debenture holders that may be appointed here after, as security for the debentures/bonds that may be issued by the Company, Group Companies, Associates Companies and other person or persons together with interest, cost, charges, expenses and all other monies payable by the Company, Group Companies, Associates Companies and other person or persons to the said lender(s) and/or for the purpose of securing the securities (comprising of fully/partly convertible and/or non convertible debenture and/or any other debts instruments with or without detachable or non-detachable warrants and/or secured premium notes and/or floating rate notes/bonds or other debt instruments) together with interest, remuneration of the trustees, premium, if any, on redemption, costs, charges and expenses payable by the Company in terms of the trust deed/other documents to be finalized and executed between the Company and the trustees/lenders and containing such specific terms and conditions (which may include authorization to the lender to transfer /assignment of security in favour of third party) and covenants in that behalf and agreed to between the Board of Directors and the trustees /lenders, up to a value of and within the overall limits of Rs. 30 Crores (Rupees Thirty Crore Only).”

“RESOLVED FURTHER THAT the Board be and is hereby authorized to take such steps as may be necessary for obtaining approvals, statutory, contractual or otherwise, in relation to the above and to settle all matters arising out of and incidental thereto, and to sign and to execute deeds, applications, documents and writings that may be required on behalf of the Company and generally to do all such acts, deeds, matters and things as may be necessary, proper, expedient or incidental for giving effect to this resolution.”

5. TO TAKE APPROVAL FOR ENHANCING THE BORROWING LIMITS OF THE COMPANY UNDER SECTION 180(1)(C) OF THE COMPANIES ACT, 2013

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

“RESOLVED THAT in supersession of all the earlier resolutions passed and pursuant to the provisions of section 180(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company

to borrow money, as and when required, from banks, financial institutions, foreign lenders, any other corporate entities, authorities, through any other instruments either in Indian Rupees or any other such foreign currencies as may be permitted under law from time to time, notwithstanding that money so borrowed together with the monies already borrowed by the company, if any, apart from temporary loans, obtained from the company's bankers in the ordinary course of business, may exceed the aggregate of the paid up capital of the company and its free reserves, provided that the total amount so borrowed by the board shall not at any time exceed Rs. 30 Crores (Rupees Thirty Crore Only) or limits so prescribed under Section 180(1)(c), as may be amended from time to time, whichever is higher.

"RESOLVED FURTHER THAT the board of Directors of the company, be and is hereby authorized to do all such acts, deeds, matters and things as may be deemed necessary, expedient or incidental for giving effect to the above resolution."

6. TO ALTER THE MAIN OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to provisions of Section 4 and 13 of the Company Act, 2013 and all other applicable provisions, if any, of the Companies Act, 2013 including any statutory modifications or re-enactment thereof for the time being in force and rules made there under and subject to requisite approval of the Registrar of Companies, Punjab and Chandigarh and all other relevant authorities governed by SEBI, if any, the consent of the members of the Company be and is hereby accorded to insert new clauses mentioned below in addition to the existing clauses in the Main Object clause i.e Clause III(A) of the Memorandum of Association of the company. New clauses are as follows:

(9). To carry on the business of agriculture, plantation, growers, manufacturers, traders, cultivators, distributors, importers, exporters of agriculture produce of all descriptions like seeds, vegetable, fruits and herbs and to cultivate, grow, produce or deal in vegetable, fruits, vegetable, seeds, all types of cereal, grains, pulses, food crops and herbal products and to undertake the activities for its processing, import, export, preservation or storage with the installation for plant, machinery, cold storage, air conditioning, refrigeration and other equipments and to provide support services.

(10). To cultivate, grow, produce or deal in Bamboo Plantation, wooden and forest plants, agriculture produce and to acquire, hold, buy or acquire freehold or leasehold agriculture land, farm, garden or any other, property and to act as growers not limited to corn, hay, straw, seeds, feed stock for animals and dealers of agriculture produce and setting up ancillary production plants to utilize agriculture produces.

(11). To set up oxygen parks and to carry on the business of producers, refiners, processors, generators, accumulators, manufacturers, buyers, sellers, distributors, importers, exporters, wholesalers, retailers, traders, collaborators, of merchandising, marketing, managing, leasing, renting, developing owning, re-furnishing, repair and operating utility-scale wind and solar and other green energy projects, including distributed solar and other green energy production for commercial and industrial consumers and utilising of electricity, steam, power, solar energy, wind energy, biomass energy, geothermal energy, hydel energy, tidal and wave energy, and other conventional, non-conventional and renewable energy sources, waste treatment plants of all kinds, agro based products, ethanol, alcohol, electricity, carbon, Chemicals, Coal, Coke, Petroleum Coke products, coal tar coal tar chemicals, any other type of coke and organic chemicals based on carbon and tar derivatives, hydrocarbons, CNG Gas, liquid or gaseous petroleum and petroleum products, minerals and the products or the by-products thereof including specifically, gases, effluent gases, power, steam and bio fertilizers in India and outside India.

“RESOLVED FURTHER THAT for the purpose of giving effect to the aforesaid resolution, the Board of Directors of the Company be and is hereby authorized to take such steps and to do all such other acts and deeds as it may deem fit and appropriate and as may be necessary to settle any question, difficulty or doubt that may arise in regard to the said resolution.”

7. TO ALTER AND SUBSTITUTE CLAUSE III(B) OF THE OBJECT CLAUSE OF MEMORANDUM OF ASSOCIATION OF THE COMPANY

To consider and if thought fit, to pass, the following Resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to provisions of Section 4 and 13 of the Company Act, 2013 and all other applicable provisions, if any, of the Companies Act, 2013 including any statutory modifications or re-enactment thereof for the time being in force and rules made under there under and subject to requisite approval of the Registrar of Companies, Punjab and Chndigarh and all other relevant authorities governed by SEBI, if any, the consent of the members of the Company be and is hereby accorded to alter the existing clauses by deleting/ substituting clause 8, 11 and 12 of the objects specified in Clause III (B) of the Memorandum of Association of the company by substituting the same with the following new clauses are as follows:

(8). Subject to the provisions of Sections 73 and 179, 180 and 185 and 186 of the Companies Act, 2013 and the rules made there under and the directives of Reserve Bank of India to borrow, raise or secure the payment of money on deposit at interest for any of the purpose of the company and at such time or times and in such manner as may be thought fit and in particular by the issue of debentures or debenture stock, perpetual or otherwise including debenture or debenture stock convertible into shares in this or any other company or perpetual annuities and as security for any such money so borrowed, raised or received or any such debentures o r debenture stocks so issued to mortgage, pledge or charge the whole or any part of the property, assets or revenue and profits of the company present or future including its uncalled capital by special assignment or otherwise or to transfer or convert the same absolutely or in part and to give the lenders power of sale and other powers as may seem expedient and purchase, redeem and pay off any such securities, provided that the company shall not carry on banking business as defined in Banking Regulations Act, 1949.

(11). Subject to Section 230 to 234 of the Act, to amalgamate with any other Company with objects all or any of which are similar to the objects of the Company in any manner whatsoever (either with or without a liquidation of the Company).

(12). To pay out of the funds of the company all costs, charges and expenses and incident to the formation and registration of the Company and any company promoted by the company and issue of capital of the Company and to pay such other Company any expenses incidental to the negotiation between the promoters preliminary to the formation of the Company and other pre-incorporation or preliminary and other expenses of and also all costs, charges, duties impositions and expenses of and incidental to the accomplishment of all or any formalities which the company may think necessary or proper in connection with any of the aforesaid, subject to provisions of Section 188 of the Act.

“RESOLVED FURTHER THAT for the purpose of giving effect to the aforesaid resolution, the Board of Directors of the Company be and is hereby authorized to take such steps and to do all such other acts and deeds as it may deem fit and appropriate and as may be necessary to settle any question, difficulty or doubt that may arise in regard to the said resolution.”

8. TO INCREASE THE AUTHORIZED SHARE CAPITAL OF THE COMPANY AND AMEND THE CAPITAL CLAUSE IN THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

To consider and if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to provisions of Section 61 and 64 and any other applicable provisions, if any, of the Companies Act, 2013, including rules notified thereunder, as may be amended from time to time (including any statutory modification or re-enactment thereof for the time being in force); the consent of the members of the Company be and is hereby accorded to increase the Authorised Share Capital of the Company from Rs. 16,00,00,000/- (Rupees Sixteen Crores only) divided into 1,60,00,000 (One crore Sixty lakh) equity shares of Rs. 10/- each to Rs. 25,00,00,000/- (Rupees Twenty-Five Crores only) divided into 2,50,00,000 (Two crore Fifty lakhs) equity shares of Rs. 10/- each by creation of additional 90,00,000 (Ninety Lakhs) equity shares of Rs. 10/- each.”

“RESOLVED FURTHER THAT pursuant to provisions of Section 13, 61 and 64 and any other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force) and rules framed thereunder; the consent of the members of the Company be and is hereby accorded, for substituting Clause V of the Memorandum of Association of the Company with the following clause:

V. The Authorised Share Capital of the Company is Rs. 25,00,00,000 (Rupees Twenty-Five Crores Only) divided into 2,50,00,000 (Two crore Fifty lakhs) equity shares of Rupees 10/- (Ten Only) each.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds, matters and things as may be necessary, expedient or desirable for the purpose of giving effect to the aforesaid resolutions and in connection with any matter incidental thereto.”

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27/08/2021
Place: Mohali

Swati Vijan
Company Secretary / Compliance Officer
ACS:39179

NOTES:

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 and Rules framed thereunder, in respect of the Special Business under Item Nos. 3,4,5,6,7 & 8 of the accompanying Notice are annexed hereto.
2. In view of the current extraordinary circumstances due to COVID-19 pandemic, social distancing is a norm to be followed and pursuant to the Circular No. 14/ 2020 (dated April 8, 2020), Circular No.17/2020 (dated April 13, 2020) Circular No. 20/2020 (dated May 5, 2020), and Circular No. 02/2021 (dated January 13, 2021) (Collectively referred to as MCA Circulars), issued by the Ministry of Corporate Affairs (MCA) physical attendance of the Members to the Annual General Meeting (AGM) venue is not required and AGM be held through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC and Members of the Company joining through VC shall be reckoned for the purpose of quorum under Section 103 of the Act. Further, all resolutions in the meeting shall be passed through the facility of e-Voting/ electronic system
3. Pursuant to the Circular No. 14/2020 dated April 8, 2020, issued by the MCA the facility to appoint proxy to attend and cast vote for the Members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC and participate thereat and cast their votes through e-Voting.
4. In compliance with MCA Circular No. 20/2020 dated May 5, 2020 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI Circular No. SEBI/HO/CFD/CMD2/CIR/ P/2021/11 dated January 15, 2021 and owing to the difficulties involved in dispatching of physical copies of the financial statements including Board's Report, Auditor's report or other documents required to be attached therewith (together referred to as Annual Report FY21) and Notice of AGM are being sent in electronic mode to Members whose e-mail address is registered with the Company or the Depository Participant(s) as on **August 27, 2021** and to all other persons so entitled. The Notice of AGM and the copies of audited financial statements, board's report, auditor's report etc. will also be displayed on the website (www.ajoonibiotech.com) of the Company.
5. The Members can join the AGM in the VC mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC will be made available for 1,000 Members on first come first served basis. However, this number does not include the large Shareholders i.e. Shareholders holding 2% or more shareholding, Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairman of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
6. National Securities Depositories Limited ("NSDL") will be providing facility for voting through remote e-Voting, for participation in the 11th AGM through VC/OAVM Facility and e-Voting during the 11th AGM.
7. Attendance of the Members participating in the 11th AGM through VC/OAVM Facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
8. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India ("ICSI") and Regulation 44 of Listing Regulations read with MCA Circulars and SEBI Circular, the Company is providing remote e-Voting facility to its Members in respect of the business to be transacted at the 11th AGM and facility for those Members participating in the 11th AGM to cast vote through e-Voting system during the 11th AGM.

9. Pursuant to Section 91 of the Companies Act, 2013 and Rule 10 of the Companies (Management and Administration) Rules, 2014 read with Regulation 42(5) of the Listing Regulations, the Share Transfer Books and Register of Members of the Company will remain closed from Tuesday, 21st September, 2021 to Monday, 27th September, 2021 (both days inclusive).
10. A member may participate in the meeting even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the meeting.
11. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date only shall be entitled to avail the facility of remote e-voting.
12. M/s. Nitin Kumar & Associates, Practicing Company Secretaries, Chandigarh has been appointed as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
13. The Scrutinizer shall, immediately after the conclusion of e-voting at Annual General Meeting, download the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. Scrutinizer shall within 48 hours of conclusion of the meeting submit a consolidated scrutinizer report of the total votes cast in favor or against, if any, to the Chairman or a person authorized by him in writing.
14. The results along with the Scrutinizers Report shall be placed on the website of the Company and on the website of NSDL and also be immediately forwarded to Stock Exchange.
15. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013 will be available for inspection by the members at the Annual General Meeting of the Company.
16. The Register of Contracts or Arrangements in which the Directors are interested, maintained under Section 189 of the Companies Act, 2013 will be available for inspection by the Members at the Annual General Meeting of the Company.
17. The Ministry of Corporate Affairs (MCA), Government of India has introduced 'Green Initiative in Corporate Governance' by allowing paperless compliance by the Companies for service of documents to their Members through electronic mode, which will be in compliance with Section 20 of the Companies Act, 2013 and Rules framed there under.
18. The transfer of Unclaimed Dividend to Investor Education & Protection Fund of the Central Government as required in terms of Section 124 of the Companies Act, 2013, during the current Financial Year is not applicable.
19. The deemed venue for 11th-AGM shall be the Registered Office of the Company.
20. Since the AGM will be held through VC/OAVM Facility, the Route Map is not annexed in this Notice.
21. Information as required under Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and the Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI), in respect of the Directors seeking appointment / re-appointment at the AGM is provided under a separate heading, which forms part of this Notice.
22. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number

(PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit the PAN to their depository participants with whom they are maintaining their demat accounts. Members holding shares in physical form are requested to submit their PAN details to the Company.

23. Pursuant to Section 108 of the Companies Act, 2013, read with the relevant Rules of the Act, the Company is pleased to provide the facility to Members to exercise their right to vote by electronic means. The Members desiring to vote through electronic mode may refer to the detailed procedure on e-voting given hereinafter.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERALMEETING ARE AS UNDER:-

The remote e-Voting period begins on Thursday, September 23, 2021 at 09:00 A.M. and ends on Sunday, September 26, 2021 at 5:00 P.M. The remote e-Voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members/ Beneficial Owners as on the record date (cut-off date) i.e. September 20, 2021 may cast their vote electronically. The voting right of Shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being September 20, 2021.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:


Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual Shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email ID in their demat accounts in order to access e-Voting facility.

Login method for Individual Shareholders holding securities in demat mode is given below:

Type of Shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<p>If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com/ either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under “IDeAS” section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on options available against Company name or e-Voting service provider-NSDL and you will be redirected to NSDL e-Voting website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com.</p>

	<p>Select “Register Online for IDeAS” Portal or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</p> <p>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsd.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/ Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/ OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on options available against Company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.</p> 
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<p>Existing users who have opted for Easi/ Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi/ Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. After successful login of Easi/ Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote.</p> <p>If the user is not registered for Easi/ Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective</p>

	ESP i.e. NSDL where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/ CDSL for e-Voting facility. Once login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on options available against Company name or e-Voting service provider-NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget UserID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

B) Login Method for e-Voting and joining virtual meeting for Shareholders other than Individual Shareholders holding securities in demat mode and Shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/ Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/ OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
---	-------------------------

a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the Company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for Shareholders other than Individual Shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the Company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, please follow steps mentioned below in process for those Shareholders whose email IDs are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on **"Forgot User Details/ Password?"** (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) **"Physical User Reset Password?"** (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/ folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system. How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for Shareholders

- I) Institutional Shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimens signature of the duly authorized signatory (ies) who are authorized to vote, to the Scrutinizer by e-mail to csnitinchandigarh@gmail.com with a copy marked to evoting@nsdl.co.in.
- II) It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-Voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/ Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- III) In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-Voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to NSDL at evoting@nsdl.co.in
- IV) **Process for those Shareholders whose email ID are not registered with the depositories for procuring user id and password and registration of email IDs for e-Voting for the resolutions set out in this notice and for obtaining Notice and Annual Report:**
 - a) In case shares are held in physical mode please provide Folio No., Name of Shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to cs@ajoonibiotech.com.
 - b) In case shares are held in demat mode, please provide DPID-CLID (16-digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to cs@ajoonibiotech.com. If you are an Individual Shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method fore-Voting and joining virtual meeting for Individual Shareholders holding securities in demat mode.**
 - c) Alternatively Shareholders/ Members may send a request to evoting@nsdl.co.in for procuring user id and password for e-Voting by providing above mentioned documents.
 - d) In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to

update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

FOR HELP IN CONNECTION WITH VOTING BY ELECTRONIC MEANS OR FOR PARTICIPATING IN THE AGM THROUGH VC:

Members can directly contact NSDL, 4th Floor, 'A' Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai- 400 013. email ID: evoting@nsdl.co.in, Toll free no.: 1800 1020 990 and 1800 22 44 30. Members may also write to the Company Secretary at the email ID: cs@ajoonibiotech.com.

PROCEDURE TO RAISE QUESTIONS/ SEEK CLARIFICATIONS WITH RESPECT TO ANNUAL REPORT

- a) As the AGM is being conducted through VC, Members are encouraged to express their views/ send their queries in advance mentioning their name, DP ID and Client ID/ Folio No., e-mail ID, mobile number at cs@ajoonibiotech.com to enable smooth conduct of proceedings at the AGM. Questions/ Queries received by the Company on or before **Thursday, September 23, 2021** on the aforementioned e-mail id shall only be considered and responded to during the AGM.
- b) Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their Name, DP ID and Client ID/ Folio Number, PAN, Mobile Number at cs@ajoonibiotech.com on or before **Thursday, September 23, 2021**. Those Members who have registered themselves as a Speaker will only be allowed to express their views/ ask questions during the AGM.
- c) The Company reserves the right to restrict the number of questions and number of speakers, depending on the availability of time for the AGM.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

- 1) Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
- 2) Members are encouraged to join the Meeting through Laptops for better experience.
- 3) Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- 4) Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- 5) Share holders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at (company email id). The same will be replied by the company suitably.
- 6) Registration of Speaker related point needs to be added by company.

- 7) Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

- 1) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
- 2) Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
- 3) Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
- 4) The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021
Place: Mohali

Swati Vijan
Company Secretary & Compliance Officer
ACS:39179

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013**ITEM No. 3. TO CONSIDER AND TAKE APPROVAL FOR RELATED PARTY TRANSACTIONS**

To ensure stability of supplies in terms of quality and logistics, your Company proposes to enter into transaction(s) with the parties mentioned below. The quantity to be purchased from them will be based on actual price. The total value of the proposed transaction(s) could reach Rs. 75 Crores during financial year 2021-22 in aggregate which will be carried out at Arm's Length price and in the ordinary course of business transaction.

Section 188 of the Act and the applicable Rules framed there under provide that any Related Party Transaction will require prior approval of shareholders through ordinary resolution, if the aggregate value of transaction(s) amounts to 10% or more of the annual turnover of the Company as per last audited financial statements of the Company. During the Financial Year 2020-21, your Company has entered into certain business transactions with the Companies, which are "Related Party" as defined under Section 2 (76) of the Companies Act, 2013. The Company is also proposed to enter into certain business transactions with the same during Financial Year 2021-22. Hence, approval of the shareholders is being sought for the said Related Party Transaction(s) proposed to be entered into by your Company in the financial year 2021-22. Related Party disclosures are required under the Accounting standard (AS-18) on "Related Party Disclosures" issued by the Institute of Chartered Accountants of India are given below:-

S. No.	Name of the Related Party	Nature of Relation	Nature of Transactions
01	Healthy Biosciences Private Limited	Company is a Promoter of Ajooni Biotech Limited.	Contract for purchase & sale of goods shall be on a continuous basis. Further, leasing of properties on yearly basis.
02	Prism Medico & Pharmacy Ltd	Company is a Promoter of Ajooni Biotech Limited.	Contract for purchase & sale of goods shall be on a continuous basis.
03	Punjab Biotechnology Park Limited	Mr. Jasjot Singh, being common Director in Ajooni Biotech Limited and Punjab Biotechnology Park Limited	Contract for purchase & sale of goods shall be on a continuous basis.
04	M/s. Khanna Solvex	Mr. Jasjot Singh, Partner in the firm.	Contract for purchase & sale of goods shall be on a continuous basis.
05	Mr. Jasjot Singh	Managing Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made
06	Mr. Gursimran Singh	Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made
07	Mr. Partek Singh	Director of Ajooni Biotech Limited	Expenses incurred/ Rent paid on our behalf or any repayment made

And this year, the transactions with the above mentioned related parties are likely to increase. Thus, the approval of members is required to enter into such transactions. The Board of Directors recommends passing of the resolution as set out at item no. 3 of this Notice as an Ordinary Resolution.

ITEM No. 4 TO TAKE APPROVAL UNDER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013 TO SELL, LEASE OR OTHERWISE DISPOSE OFF, TO MORTGAGE/ CREATE CHARGES ON THE PROPERTIES OF THE COMPANY AND IN THIS REGARD.

Keeping in view the company's existing and future financial requirements to support its business operations, the Company may need additional funds. For this purpose, the Company may, from time to time, raise finance from

various Banks and/or Financial Institutions and/ or any other lending institutions and/or Bodies Corporate and/or such other persons/ individuals as may be considered fit, which, together with the moneys already borrowed by the Company (apart from temporary loans obtained from the Company's bankers in ordinary course of business) may exceed the aggregate of the paid-up capital and free reserves of the Company. Hence, it is proposed to increase the maximum borrowing limits upto Rs. 30 Crores from Rs. 15 crores for the Company.

Your Board of Directors recommends the Special Resolution as set out at Item No. 4 of the accompanying Notice, for members' approval. None of the Directors or Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the Special Resolution except to the extent of their shareholding in the Company.

ITEM No. 5 TO TAKE APPROVAL FOR ENHANCING THE BORROWING LIMITS OF THE COMPANY UNDER SECTION 180(1)(C) OF THE COMPANIES ACT, 2013.

As per the provisions of Section 180(1)(c) of the Companies Act, 2013 the Board of Directors of a Company could borrow money together with the moneys already borrowed by the Company in the ordinary course of business, to the extent of aggregate of paid up share capital and free reserves. If the borrowing exceeds the above limits, the approval of the members of the Company in General Meeting by way of Special Resolution has to be obtained.

As you know that for business and operational purposes Company borrows funds and may borrow funds from time to time and so, therefore, it is required to obtain approval of members by way of special resolution in general meeting to authorize to the Board to borrow funds in excess of the paid up share capital and free reserves.

Your Board decided to increase the limit of borrow to funds upto Rs. 30 Crores from Rs. 15 crores and recommend passing of this resolution by way of Special Resolution as set out at Item No. 5 of the accompanying Notice, for members' approval. None of the directors or their relative be deemed interested in the resolution.

ITEM No. 6 TO ALTER THE OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

The members are informed that the company is primarily involved in the manufacturing business of animal feed and supplements. Further, considering the business expansion strategies, in addition to the primary business, the company has decided to explore and diversify into the new area of business activities i.e. to deal in Bamboo Plantation, agriculture produce, setting up ancillary production plants to utilize agriculture produces and to set up oxygen parks, solar and other green energy projects including CNG Gas and other related activities as detailed in the resolution itself. In order to carry out these activities, the object clause of the memorandum of Association of the company needs to be altered.

As per the provisions of Section 13 of the Companies Act, 2013, alteration of the Object Clause i.e. Clause III (A) requires the consent of members of the company by means of a special resolution. Hence your Board recommends the passing of the proposed resolution as a special resolution for alteration in the Object Clause of the Memorandum of Association of the company as set out at Item No. 6 of the accompanying Notice, for members' approval. None of the Directors/Members of the Company are concerned or interested in the proposed resolution.

ITEM No. 7 TO ALTER AND SUBSTITUTE CLAUSE III(B) OF THE OBJECT CLAUSE OF MEMORANDUM OF ASSOCIATION OF THE COMPANY

The members are informed that company needs to alter the existing clauses by deleting/ substituting clause 8,11 and 12 of the objects specified in Clause III (B) of the Memorandum of Association of the company by substituting

the same as per Companies Act 2013. The proposal to substitute the clauses is required to align the same as per the provisions of Section 13 of the Companies Act, 2013.

As per the provisions of Section 13 of the Companies Act, 2013, alteration of the Object Clause i.e. Clause III (B) requires the consent of members of the company by means of a special resolution. Hence your Board recommends the passing of the proposed resolution as a special resolution for alteration in the Object Clause of the Memorandum of Association of the company as set out at Item No. 7 of the accompanying Notice, for members' approval. None of the Directors/Members of the Company are concerned or interested in the proposed resolution.

ITEM NO. 8 TO INCREASE THE AUTHORISED SHARE CAPITAL OF THE COMPANY AND AMEND THE CAPITAL CLAUSE IN THE MEMORANDUM OF ASSOCIATION OF THE COMPANY

At present the Authorised Share Capital of the Company is 16,00,00,000 (Rupees Sixteen Crores Only) divided into 1,60,00,000 (One Crore Sixty lakhs only) equity shares of Rs. 10/- each out of which paid up share capital of the Company is Rs. 10,00,55,820/- (Rupees Ten Crore Fifty Five Thousand Eight Hundred and Twenty Only) divided into 1,00,05,582 (One Crore Five Thousand Five Hundred and Eighty Two) equity shares of Rs. 10/- each.

Considering the increased fund requirements of the Company, the Board at its Meeting held on 27th August, 2021, had accorded its approval for increasing the Authorised Share Capital from Rs. 16,00,00,000 (Rupees Sixteen crore) to Rs.25,00,00,000 (Rupees Twenty Five Crore) by creation of 90,00,000 (Ninety Lakhs) additional equity share of Rs.10/- each, subject to shareholders' approval. It is therefore proposed to increase the Authorised Share Capital of the Company from Rs. 16,00,00,000 (Rupees Sixteen crore) to Rs.25,00,00,000 (Rupees Twenty Five Crore) by creation of 90,00,000 (Ninety Lakhs) additional equity share of Rs.10/- each ranking paripassu with the existing Equity Shares in all respects as per the Memorandum and Articles of Association of the Company.

Consequently, Clause V of the Memorandum of Association would also require alteration so as to reflect the changed Authorised Share Capital.

The proposal for increase in Authorised Share Capital and amendment of Memorandum of Association of the Company requires approval of members at a general meeting.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives, are in any way concerned or interested, financially or otherwise in the said resolution. The consent of the members is, therefore, being sought for passing the aforesaid resolution NO. 8 of the notice as an **Ordinary Resolution**.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27/08/2021
Place: Mohali

Swati Vijan
Company Secretary /Compliance Officer
ACS:39179

AJOONI BIOTECH LIMITED

Registered office: D-118, Industrial Area, Phase VII, Mohali, Punjab 160055 India
 CIN:L85190PB2010PLC040162,E-mail: ajooni118@gmail.com, Website: <https://ajoonibiotech.com/>

DIRECTORS' REPORT FOR THE FINANCIAL YEAR 2020-21

To
 The Members
 Ajooni Biotech Limited

The Directors have pleasure in presenting their 11th Annual Report on the business and operations together with the Audited Statement of Accounts of the Company for the year ended 31st March, 2021.

1. FINANCIAL RESULTS

The Financial results are briefly indicated below:

Particulars	2020-21	2019-20
Revenue from Operations	51,03,88,901	40,03,26,163
Other Income	1,72,109	5,98,511
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense	1,66,58,227	13006109.42
Less: Depreciation/Amortisation/ Impairment	57,75,160	49,19,813.49
Profit/loss before Finance Costs, Exceptional items and Tax Expense	1,08,83,067	9086295.93
Less: Finance Costs	58,40,690	3279206.24
Profit/loss before Exceptional items and Tax Expense	50,42,377	4807089.69
Add/(less): Exceptional items	-	-
Profit/loss before Tax Expense	50,42,377	4807089.69
Less: Tax Expense		
Current Tax	15,03,280	1683532
Deferred Tax	(1,91,424)	(3,44,455)
MAT Credit Entitlement	-	-
Profit/loss for the year	37,30,518	34,68,012.95

2. REVIEW OF OPERATION

The Company has made profit of Rs. 37,30,518/- during the financial year. Your Directors expect to achieve better performance in the future taking maximum efforts to control the costs and optimize the results in the coming years.

3. TRANSFER TO RESERVES

The company has transferred Rs. 37,30,518/- being the profit for the current financial year to Reserves & Surplus.

4. CHANGE IN NATURE OF BUSINESS

There is no change in the nature of the business of the company.

5. MATERIAL CHANGES AFFECTING THE FINANCIAL POSITION OF THE COMPANY

During the year under review, no material change took place which may effect the financial position of the company.

6. DIVIDEND

In view to expand the business of the company and continuous investment in the business, the Directors of the Board regret their inability to recommend any dividend.

7. DEPOSITS

During the period under review the Company has neither accepted nor invited any Public Deposits. Hence the provisions of Section 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 are not applicable.

8. CHANGES IN SHARE CAPITAL, IF ANY**a) Authorised Capital**

During the year under review, Company's authorised share capital was increased from Rs. 10 crores (Rupees Ten Crore only) divided into 1,00,00,000 (One Crore only) equity shares of Rs. 10/- (Rupees Ten only) to Rs. 16 crores (Rupees Sixteen Crore only) divided into 1,60,00,000 (One Crore Sixty Lacs only) equity shares of Rs. 10/- (Rupees Ten only).

b) Issued, Subscribed & Paid up Capital

During the year under review, company issued 6,00,000 equity shares at Rs. 20 each (including premium of Rs. 15/-) on preferential basis. Further, company issued additional 10,00,558 bonus shares in the ratio of 1:9.

Therefore, Company's paid up share capital has increased from Rs. 8,40,50,240/- (Rupees Eight Crore Forty Lakhs Fifty Thousand Two Hundred and Forty only) divided into 84,05,024 (Eighty Four Lakh Five Thousand and Twenty Four only) equity shares of Rs. 10 each/- to Rs. 10,00,55,820/- (Rupees Ten Crore Fifty Five Thousand Eight Hundred and Twenty only) divided into 1,00,05,582 (One Crore Five Thousand Five Hundred and Eighty Two only) equity shares of Rs. 10 each.

9. EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in Form MGT-9 pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 is annexed herewith as **Annexure 'A'** to the Board Report. The copy of same has also been uploaded on the website of the Company at www.ajoonibiotech.com.

10. NUMBER OF MEETINGS

The Board has met 9 (Nine) times during the financial year, the details of which are as under:
02/04/2020, 29/06/2020, 13/08/2020, 07/09/2020, 05/11/2020, 10/11/2020, 23/01/2021, 01/03/2021 and 13/03/2021.

The details of meetings of the Board and attendance of the directors is provided in the Report on Corporate Governance which forms the part of this report.

11. COMPOSITION OF COMMITTEES

As per the applicable provisions of the Companies Act, 2013 & Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2018, **three** Committees have been constituted in the company which are as follows:-

- a) Audit Committee
- b) Nomination & Remuneration Committee
- c) Stakeholder Grievance Committee

The details of meetings of the committees and attendance of the members is provided in the Report on Corporate Governance which forms the part of this report.

12. DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. RE-APPOINTMENT OF DIRECTOR

During the year, Mr. Gursimran Singh (DIN: 02209675) Director of the Company retiring by rotation & being eligible offers himself for re-appointment at the ensuing Annual General Meeting.

B. INDEPENDENT DIRECTORS

The Company has received declaration from all the Independent Directors of the Company confirming that they meet with the criteria of Independence as prescribed under sub-section (6) of section 149 of the Companies Act, 2013 and under SEBI (LODR) Regulations, 2015 with the Stock Exchanges.

The meeting of the Independent Directors was held on 25th February, 2021, as per schedule IV of the Companies Act, 2013. All the directors attended the meeting.

None of the Directors of your Company is disqualified under Section 162 (2) of the Companies Act, 2013. As required by law, this position is also reflected in the Auditors' Report.

C. APPOINTMENT OF DIRECTOR

During the year, Mr. Gursimran Singh was appointed as Additional Director with effect from 13th August 2020. Further, he was regularized as a Director at the Annual General Meeting held on 10th September 2020.

D. CESSATION OF DIRECTOR

During the year, Mr. Rajesh Parashar resigned from the directorship of the company with effect from 13th August 2020.

E. KEY MANAGERIAL PERSONNEL

During the year under review, pursuant to Section 2(51) and Section 203 of the Act, read with the Rules framed there under, Key Managerial Personnel as on 31st March 2021 are the following:

- (i) Mr. Jasjot Singh- Managing Director
- (ii) Mr. Gurmeet Singh- Chief Financial Officer
- (iii) Ms. Swati Vijan – Company Secretary

F. REMUNERATION

The details of the remuneration given to the Board of Directors and Key Managerial Personnel have been given in the **Annexure A** of the Board Report. (MGT-9)

13. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

During the financial year ended March 31, 2021, all transactions with the Related Parties as defined under the Companies Act, 2013 read with Rules framed thereunder were in the 'ordinary course of business' and 'at arm's length' basis. Your Company does not have a 'Material Subsidiary' as defined under Regulation 16(1)(c) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ['Listing Regulations'].

Further, the information on transactions with related parties pursuant to Section 134(3)(h) of the Act read with rule 8(2) of the Companies (Accounts) Rules, 2014 are given in **Annexure "B"** in Form AOC-2 and the same forms part of this report.

The Related Party Transactions Policy as approved by the Board is uploaded on the Company's website at <https://www.ajoonibiotech.com/> and direct web link to the policy is at <https://ajoonibiotech.com/Uploads/Policy/RELATED%20PARTY%20TRANSACTION%20POLICY.pdf>

14. PARTICULARS OF EMPLOYEES

Information as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, and subsequent amendments thereto, is annexed to this Board's Report and marked as **Annexure "C"**.

15. CORPORATE SOCIAL RESPONSIBILITY (CSR)

The provisions of Section 135 of the Companies Act relating to Corporate Social Responsibility are not applicable as the Company is having Net worth less than rupees Five Hundred Crore, Turnover less than rupees One Thousand Crore and Net Profit less than rupees Five Crore.

16. MANNER OF BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and regulation 17(10) of SEBI (LODR) Regulation 2015, a structured procedure was adopted after taking into consideration of the various aspects of the Board's functioning composition of the Board and its committees, execution and performance of specific duties, obligations and governance.

The performance evaluation of the independent Directors was completed in time. The performance evaluation of the Chairman and the Non-independent Directors was carried out by the Independent Directors. The Board of Directors expresses their satisfaction with the evaluation process.

The performance of each committee has been evaluated by its members and found to be highly satisfactory.

On the basis of this exercise, the Board has decided that all Independent Directors should continue to be on the Board.

17. CORPORATE GOVERNANCE

Your Company believes in adopting best practices of corporate governance and is committed to maintain the steady standards for the same. The Company has complied with all the conditions of Corporate Governance as stipulated in SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 after getting shifted to the Main Board of NSE.

The Report on corporate governance along with a certificate from the Auditors of the Company confirming the compliance as stipulated under Regulation 34 read with Schedule V of the SEBI (LODR) Regulations 2015 forms part of this Annual Report as “**Annexure D**”.

18. MANAGEMENT DISCUSSION ANALYSIS REPORT

The details forming part of Management Discussion and Analysis Report is annexed herewith as Annexure to the Board Report as **ANNEXURE “E”**.

19. SUBSIDIARIES/ ASSOCIATES/JOINT VENTURES

The Company has no subsidiary/Joint ventures/Associate Companies as per the provisions of Companies Act, 2013 during the financial year ended on 31st March, 2021.

20. ADOPTION OF INDIAN ACCOUNTING STANDARD (INDAS)

The company was listed on SME Platform (NSE emerge) and got admitted its shares on the Main Board of NSE on 07th May 2021. Further, in accordance with the Indian Accounting Standards notified under Section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards (Ind AS)) Rules, 2015, company has to adopt and follow the provisions of Indian Accounting Standards in preparation of its financial statements for the year ended 31st March 2021. The Ministry of Corporate Affairs vide notification dated 16 February 2015 made it mandatory in a phased manner for adoption and applicability of Indian Accounting Standards (Ind AS) for companies other than Banking, Insurance and Non-Banking Finance Companies read with Rule 4 of the Companies (Indian Accounting Standards) Rules 2015.

Keeping in view of the above applicability, the Company has followed the Indian Accounting Standards notified under Section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards (Ind AS)) Rules, 2015 for preparation of its financial statements for the year ended 31st March 2021.

21. DIRECTOR’S RESPONSIBILITY STATEMENT

Pursuant to the requirement under Section 134 (5) of the Companies Act, 2013, with respect to Directors Responsibilities Statement, it is hereby confirmed:

- a) That in the preparation of the annual accounts for the financial year ended 31st March, 2021 the applicable Accounting standards had been followed along with proper explanation relating to material departures.
- b) That the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year review.
- c) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities, and,
- d) The Directors had prepared the accounts for the financial year ended 31st March, 2021 on a going concern basis.
- e) The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

22. DETAILS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The Provisions of Section 134(3) (m) of the Companies Act, 2013 read with Rule 8 of Companies (Accounts) Rules, 2014 regarding Conservation of Energy and Technology Absorption do not apply to your company for the period under review. Further, there were no foreign exchange earnings or outgo during the year under review. However, the management has taken all the necessary steps to conserve the resources to the extent possible.

“Annexure – F”.

23. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

As required under section 204 (1) of the Companies Act, 2013 and Rules made there under the Company has appointed M/s. MR CHECHI & Associates, Company Secretaries, Chandigarh as Secretarial Auditor to conduct the Secretarial Audit of the Company for the financial Year 2019-20. The Secretarial Audit Report for the financial year ended 31st March 2021 is attached as “Annexure G” to this Report.

Observations	Remarks/ Reply
<p><i>During the year under review National Stock Exchange of India Limited had imposed a penalty of Rs. 11,800/- on the company for Non-compliance of Regulation 29(2)/(3) of SEBI (LODR) Regulations, 2015 and Rs. 47,200/- for Non- Compliance of SEBI (ICDR) Regulations, 2018.</i></p>	<p><i>Due to the COVID-19, the business of the Company was adversely affected, and had to deal with so much uncertainty. Therefore, in order to deal the then situation, the Audit committee actively recommended the matter to the Board for to raise funds for smooth working and to meet the working requirements.</i></p> <p><i>In order to deal with the prevailing situation, your Board urgently took up the matter within any other business matter, and intimated to the stock exchange. However, company did not have any intention to conceal such information. No unfair advantage or gain has occurred to company and also no harm or loss was caused to any retail investors.</i></p> <p><i>Therefore, the penalty imposed by the stock exchange was just regarding the non-disclosure of information on time and the same was paid by the company at the same time. The default was purely un-intentional.</i></p>
<p><i>The company did not publish the Notice of Annual General Meeting held on 10th September, 2020</i></p>	<p><i>During the year under review, company was listed on NSE Emerge (SME Platform) and was exempted under Regulation 47 (4) of SEBI (LODR) Regulation 2015 to publish Advertisements in the Newspapers. However, in line with the SEBI circular, the Ministry of Corporate Affairs ("MCA") issued a circular on 05th May 2020, exempted the companies to dispatch Notice of AGM and Annual Reports to the shareholders through registered post or speed post or courier and shall be sent only through e-mail and a public notice shall be e by way of advertisement be published specifying the information of AGM. However, the company uploaded Notice of AGM and Annual Report on the website of the company and disclosed to the stock exchange, whenever and wherever required, hence, complied with the aforementioned SEBI Circular but, since the Company Secretary of the company was on leave and there was no other person to follow the</i></p>

	<p><i>part, the compliance with the aforementioned MCA Circular got skipped.</i></p> <p><i>Further, there was no mala-fide intention, not to comply with the guidelines and is completely un-intentional.</i></p>
--	---

24. STATUTORY AUDITORS & AUDITORS REPORT

M/s Harjeet Parvesh & Company (FRN NO. 017437N), Chartered Accountants (Peer Review Certificate No. 011668) were re-appointed as Statutory Auditors of the Company at the Annual General Meeting held on 30th September 2019, for the second term of five consecutive years i.e. for a period of five years commencing from the conclusion of this Annual General Meeting till the conclusion of the 14th Annual General Meeting of the Company to be held in the year 2024 and shall continue to be statutory auditors of the company for the Financial Year 2021-2022. The Auditors have confirmed that they are not disqualified from being re-appointed as Auditors of the Company. The Report given by the Auditors on the financial statement of the Company is part of this Report as **Annexure “H”**.

There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report. During the year under review, the Auditors had not reported any matter under Section 143 (12) of the Companies Act, 2013.

25. CASH FLOW ANALYSIS

In conformity with the provisions of Clause 34(2) of SEBI (LODR) Regulations, 2015, the Cash Flow Statement for the year ended on 31st March, 2021 forms an integral part of the Financial Statements.

26. IMPLEMENTATION OF RISK MANAGEMENT POLICY

The Company does not have any Risk Management Policy as the elements of risk threatening the Company’s existence are very minimal during the financial year ended on 31st March, 2021.

27. NOMINATION & REMUNERATION COMMITTEE POLICY

Your Board has framed a policy which lays down a framework in relation to remuneration of Directors, Key Managerial Personnel and Senior Management Personnel of the Company. This policy also lays down criteria for selection and appointment of Board Members. The detail of this policy is explained in the Report on Corporate Governance. The Nomination and remuneration Policy is available on the website of the company at www.ajoonibiotech.com and direct web link to the policy is at <https://ajoonibiotech.com/Uploads/Policy/nomination-and-remuneration-policy.pdf>

28. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not given any loan/guarantee or provided any security during the year under review under the provisions of section 186 of the Companies Act, 2013.

Details of Loans

Sl. No.	Date of making loan	Details of Borrower	Amount	Purpose for which the loan is to be utilized by the recipient	Time period for which it is given	Date of BR	Date of SR (if reqd.)	Rate of Interest	Security

<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>
------------	------------	------------	------------	------------	------------	------------	------------	------------	------------

Details of Investments

Sl. No.	Date of investment	Details of Investee	Amount	Purpose for which the proceeds from investment is pro- posed to be utilized by the recipient	Date of BR	Date of SR (if reqd.)	Expected rate of return
<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>

Details of Guarantee / Security Provided

Sl. No	Date of providing security/ guarantee	Details of recipient	Amount	Purpose for which the proceeds from investment is pro- posed to be utilized by the recipient	Date of BR	Date of SR (if reqd.)	Expected rate of return
<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>	<i>NIL</i>

29. BORROWINGS

Total borrowings of the company both long term and short term as on 31st March, 2021 are amounting Rs. 678 lacs as compared to previous year ended 31st March, 2020 of amounting Rs. 502 lacs (For details Refer Note No. 11 and 12 of the Audited Financial Statements).

30. WHISTLE BLOWER POLICY AND VIGIL MECHANISM

Section 177(9) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, inter alia, provides for a mandatory requirement for all listed companies to establish a mechanism called the 'Whistle Blower Policy' for Directors and employees to report concerns of unethical behavior, actual or suspected, fraud or violation or the Company's code of conduct or ethics policy. In line with this requirement, the Company has framed a "Whistle Blower Policy", which is placed on the Company's website. The Whistle Blower Policy as approved by the Board is uploaded on the Company's website at <https://www.ajoonibiotech.com/> and direct web link to the policy is at https://ajoonibiotech.com/Uploads/Policy/whistle_blower_policy.pdf.

31. DISCLOSURES UNDER SEXUAL HARRASMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company has in place a 'Prevention of Sexual Harassment Policy' pursuant to the Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. An Internal Complaints Committee has also been set up to redress complaints received regarding sexual harassment. All employees (Permanent, contractual, temporary, trainees) are covered under this policy. No complaint has been received during the year under review.

32. STOCK EXCHANGES

Your board is pleased to announce that the shares of the company were shifted from SME Platform (NSE emerge) to the Main Board of National Stock Exchange of India Limited (NSE). Your company successfully

completed 2 years on SME Platform of NSE and met the eligibility criteria for shifting to the main board of NSE. The company had obtained In-Principle approval from NSE on April 26, 2021 and Final Listing and Trading Approval was granted by NSE on May 05, 2021. Further, 10005582 equity shares of the company were listed and admitted for dealing on exchange w.e.f. May 07, 2021.

33. LISTING FEES

The Annual Listing Fee for the financial year 2020-21 had been paid to the National Stock Exchange where the Company's shares are listed.

34. TRADE RELATIONS

The Board wishes to place on record its appreciation for the support and co-operation that the Company received from its suppliers, distributors, retailers and other associates. The Company has always looked upon them as partners in its progress and has happily shared with them rewards of growth. It will be Company's endeavor to build and nurture strong links based on mutuality, respect and co-operation with each other and consistent with customer interest.

35. INTERNAL AUDITORS & AUDITORS REPORT

As required under section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 made there under, the Company has appointed Internal Auditors to assess the risk management and to ensure that risk management processes are efficient, effective, secure and compliant. It is the basic check of internal control of the organization. An internal audit is an organizational move to check, ensure, monitor and analyze its own business operations in order to determine how well it conforms to a set of specific criteria.

36. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

Your Company's internal financial control ensures that all assets of the Company are properly safeguarded and protected, proper prevention and detection of frauds and errors and all transactions are authorized, recorded and reported appropriately.

Your Company has an adequate system of internal financial controls commensurate with its size and scale of operations, procedures and policies, ensuring orderly and efficient conduct of its business, including adherence to the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, and timely preparation of reliable financial information.

37. MAINTENANCE OF COST RECORDS

The Central Government has not prescribed the maintenance of cost records under Section 148(1) of the Companies Act, 2013 and Rules framed thereunder with respect to the Company's nature of business.

38. DEMATERILISATION OF SHARES

The Company has connectivity with NSDL & CDSL for dematerialization of its equity shares. The ISIN No. INE820Y01013 has been allotted for the Company. Further the Company does not have any Equity shares lying in the Suspense Account.

39. TRANSFER TO INVESTOR PROTECTION AND EDUCATION FUND (IEPF)

There are no unclaimed funds or shares to be deposited to the Investor Protection and Education Fund as on 31.03.2021.

40. COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND GENERAL MEETINGS

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (ICSI).

41. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There were no significant and material orders passed by the Regulators, Courts or Tribunals, during the year under review, which would impact the going concern status of the Company and its operations in future.

42. ACKNOWLEDGEMENTS

Your Directors would like to express their appreciation for assistance and co-operation received from the financial institutions, banks, Government authorities, customers, vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the executives, staff and workers of the Company and the shareholders for their support and confidence reposed on the Company.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021
Place: Mohali

Jasjot Singh
Managing Director
DIN: 01937631

Gursimran Singh
Director
DIN: 02209675

ANNEXURE 'A' TO DIRECTORS' REPORT

MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON MARCH 31, 2021

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i.	CIN	L85190PB2010PLC040162
ii.	Registration Date	17/02/2010
iii.	Name of the Company	AJOONI BIOTECH LIMITED
iv.	Category/Sub-Category of the Company	COMPANY LIMITED BY SHARES
v.	Address of the Registered office and contact details	D-118, Industrial Area, Phase VII, Mohali-160055 Phone:- 0172-5020761
vi.	Whether listed company	Yes (NSE Emerge) *company has migrated from SME to Main Board of NSE w.e.f. 07 th May 2021
vii.	Name, Address and Contact details of Registrar and Transfer Agent, if any	Cameo Corporate Services Ltd. Subramanian Building No 1, Club House Road, Chennai - 600 002.

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sr. No.	Name and Description of main products/ services	NIC Code of the Product/ service	% to total turnover of the company
1.	Manufacture of cattle feed	10801	99.64%
2.	Manufacture of veterinary preparations	21005	0.36%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: NIL

Sr. No.	Name And Address Of The Company	CIN	% of shares held
NIL			

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) CATEGORY-WISE SHARE HOLDING

Category of Shareholders	No. of Shares held at the beginning of the year (01/04/2020)				No. of Shares held at the end of the year (31/03/2021)				% Change during The year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter									
1) Indian									
a) Individual/ HUF	1988128	0	1988128	23.65	3137916	0	3137916	31.36	7.70

b) Central Govt.									
c) State Govt(s)									
d) Bodies Corp	1897896	0	1897896	22.58	2028772	0	2028772	20.27	-2.30
e) Banks / FI									
f) Any Other									
Sub-total(A)(1):-	3886024	0	3886024	56.33	5166688	0	5166688	51.63	5.40
2) Foreign									
g) NRIs- Individuals	-	-	-	-	-	-	-	-	-
h) Other- Individuals	-	-	-	-	-	-	-	-	-
i) Bodies Corp.	-	-	-	-	-	-	-	-	-
j) Banks / FI	-	-	-	-	-	-	-	-	-
k) Any Other....	-	-	-	-	-	-	-	-	-
Sub-total(A)(2):-	-	-	-	-	-	-	-	-	-
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt.	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total(B)(1)	-	-	-	-	-	-	-	-	-
2. Non Institutions									
a) Bodies Corp. (i) Indian (ii) Overseas	2135000	0	2135000	25.40	2283346	0	2283346	22.82	-2.58
b) Individuals (i) Individual shareholders holding nominal share capital upto Rs. 1 lakh*	1224000	0	1224000	14.56	1007849	0	1007849	10.07	-4.48
(ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh*	948000	0	948000	11.27	1395521	0	1395521	13.94	2.66
c) Others(Specify) (Bodies Corporate, HUF,	212000	0	212000	2.52	152178	0	152178	1.52	-5.40

Foreign Ind. or NRI and Clearing Members)									
Sub-total(B)(2)	4519000	0	4519000	53.76	4838894	0	4838894	48.36	-5.40
Total Public Shareholding (B)=(B)(1)+ (B)(2)	4519000	0	4519000	53.76	4838894	0	4838894	48.36	-5.40
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	8405024	0	8405024	100	10005582	0	10005582	100	0

ii) SHAREHOLDING OF PROMOTERS:

Sr. No	Shareholder's Name	Shareholding at the beginning of the year (01.04.2020)			Shareholding at the end of the year (31.03.2021)			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	JASJOT SINGH	702050	8.35	0	1686720	16.85	0	+9.84
2.	ASHMEET KAUR	27	0.00	0	30	0.00	0	-
3.	UPNEET KAUR	697247	8.30	0	774718	7.74	0	-0.77
4.	PARMJEET KAUR	27	0.00	0	30	0.00	0	-
5.	ISHNEET KAUR	588777	7.01	0	676418	6.76	0	-0.25
6.	HEALTHY BIOSCIENCES PRIVATE LIMITED	1244067	14.8	0	1382296	13.82	0	-1.38
7.	PRISM MEDICO AND PHARMACY LIMITED	653829	7.78	0	646476	6.46	0	-0.07

iii) CHANGE IN PROMOTERS' SHAREHOLDING (PLEASE SPECIFY, IF THERE IS NO CHANGE) :

Sl No	Name of the Share holder	Shareholding at the beginning of the year (01.04.2020)		Cumulative Shareholding during the year (31.03.2021)	
		No of shares	% of total shares of the company	No of shares	% of total shares of the company
1	HEALTHY BIOSCIENCES PRIVATE LIMITED				
	At the beginning of the year 01-Apr-2020	1244067	14.8014	1244067	14.8014
	BONUS	138229	1.3815	1382296	13.8152
	At the end of the Year 31-Mar-2021	1382296	13.8152	1382296	13.8152
2	JASJOT SINGH				
	At the beginning of the year 01-Apr-2020	702050	8.3527	702050	8.3527

	Purchase 10-Jul-2020	20000	0.1998	722050	7.2164
	Purchase 31-Jul-2020	12000	0.1199	734050	7.3364
	Purchase 07-Aug-2020	20000	0.1998	754050	7.5362
	Purchase 14-Aug-2020	16000	0.1599	770050	7.6962
	Purchase 21-Aug-2020	20000	0.1998	790050	7.8960
	Purchase 28-Aug-2020	128000	1.2792	918050	9.1753
	Purchase 27-Nov-2020	600000	5.9966	1518050	15.1720
	BONUS	168670	1.6857	1686720	16.8577
	At the end of the Year 31-Mar-2021	1686720	16.8577	1686720	16.8577
3	UPNEET KAUR				
	At the beginning of the year 01-Apr-2020	697247	8.2955	697247	8.2955
	Purchase 26-Mar-2021	77471	0.7742	774718	7.7428
	At the end of the Year 31-Mar-2021	774718	7.7428	774718	7.7428
4	PRISM MEDICO AND PHARMACY LIMITED				
	At the beginning of the year 01-Apr-2020	653829	7.7790	653829	7.7790
	Sale 08-Jan-2021	-72000	0.7195	581829	5.8150
	BONUS	64647	0.6461	646476	6.4611
	At the end of the Year 31-Mar-2021	646476	6.4611	646476	6.4611
5	ISHNEET KAUR				
	At the beginning of the year 01-Apr-2020	588777	7.0050	588777	7.0050
	Purchase 26-Mar-2021	65419	0.6538	654196	6.5383
	At the end of the Year 31-Mar-2021	654196	6.5383	654196	6.5383
	HAVING SAME PAN				
5	ISHNEET KAUR				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 25-Sep-2020	8000	0.0799	8000	0.0799
	Purchase 30-Sep-2020	12000	0.1199	20000	0.1998
	BONUS	2222	0.0222	22222	0.2220
	At the end of the Year 31-Mar-2021	22222	0.2220	22222	0.2220
6	ASHMEET KAUR				
	At the beginning of the year 01-Apr-2020	27	0.0003	27	0.0003
	BONUS	3	0.0000	30	0.0002
	At the end of the Year 31-Mar-2021	30	0.0002	30	0.0002
7	PARMJEET KAUR				
	At the beginning of the year 01-Apr-2020	27	0.0003	27	0.0003
	BONUS	3	0.0000	30	0.0002
	At the end of the Year 31-Mar-2021	30	0.0002	30	0.0002

iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

SI No	Name of the Share holder	Shareholding at the beginning of the year (01.04.2020)		Cumulative Shareholding during the year (31.03.2021)	
		No of shares	% of total shares of the company	No of shares	% of total shares of the company

1	PRITIKA AUTO INDUSTRIES LIMITED				
	At the beginning of the year 01-Apr-2020	937500	11.1540	937500	11.1540
	BONUS	104166	1.0410	1041666	10.4108
	Sale 31-Mar-2021	-22220	0.2220	1019446	10.1887
	At the end of the Year 31-Mar-2021	1019446	10.1887	1019446	10.1887
2	PRITIKA ENGINEERING COMPONENTS PVT LTD				
	At the beginning of the year 01-Apr-2020	937500	11.1540	937500	11.1540
	BONUS	104166	1.0410	1041666	10.4108
	Sale 19-Mar-2021	-250818	2.5067	790848	7.9040
	Purchase 26-Mar-2021	81946	0.8190	872794	8.7230
	At the end of the Year 31-Mar-2021	872794	8.7230	872794	8.7230
3	VISHAL SHARMA .				
	At the beginning of the year 01-Apr-2020	100000	1.1897	100000	1.1897
	Sale 05-Feb-2021	-64000	0.6396	36000	0.3597
	Sale 26-Feb-2021	-36000	0.3597	0	0.0000
	At the end of the Year 31-Mar-2021	0	0.0000	0	0.0000
4	ACME FINVEST PRIVATE LIMITED				
	At the beginning of the year 01-Apr-2020	100000	1.1897	100000	1.1897
	BONUS	6667	0.0666	106667	1.0660
	At the end of the Year 31-Mar-2021	106667	1.0660	106667	1.0660
5	GURSIMRAN SINGH				
	At the beginning of the year 01-Apr-2020	64000	0.7614	64000	0.7614
	Sale 03-Apr-2020	-4000	0.0399	60000	0.5996
	Purchase 01-May-2020	4000	0.0399	64000	0.6396
	Sale 10-Jul-2020	-8000	0.0799	56000	0.5596
	Sale 24-Jul-2020	-4000	0.0399	52000	0.5197
	Purchase 31-Jul-2020	8000	0.0799	60000	0.5996
	Sale 21-Aug-2020	-4000	0.0399	56000	0.5596
	Purchase 28-Aug-2020	8000	0.0799	64000	0.6396
	Sale 18-Sep-2020	-4000	0.0399	60000	0.5996
	Sale 08-Jan-2021	-40000	0.3997	20000	0.1998
	BONUS	2222	0.0222	22222	0.2220
	At the end of the Year 31-Mar-2021	22222	0.2220	22222	0.2220
	HAVING SAME PAN				
5	GURSIMRAN SINGH				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	BONUS	141	0.0014	141	0.0014
	At the end of the Year 31-Mar-2021	141	0.0014	141	0.0014

6	ANJU SARAF				
	At the beginning of the year 01-Apr-2020	56000	0.6662	56000	0.6662
	Sale 19-Feb-2021	-8000	0.0799	48000	0.4797
	BONUS	5333	0.0533	53333	0.5330
	Sale 19-Mar-2021	-4444	0.0977	43556	0.4353
	At the end of the Year 31-Mar-2021	48889	0.4886	48889	0.4886
7	RAHUL AGARWAL				
	At the beginning of the year 01-Apr-2020	52000	0.6186	52000	0.6186
	Purchase 24-Jul-2020	12000	0.1199	64000	0.6396
	Purchase 31-Jul-2020	12000	0.1199	76000	0.7595
	Sale 14-Aug-2020	-4000	0.0399	72000	0.7195
	Purchase 21-Aug-2020	4000	0.0399	76000	0.7595
	Purchase 28-Aug-2020	8000	0.0799	84000	0.8395
	Purchase 12-Mar-2021	24000	0.2398	108000	1.0793
	BONUS	12000	0.1199	120000	1.1993
	At the end of the Year 31-Mar-2021	120000	1.1993	120000	1.1993
	HAVING SAME PAN				
7	RAHUL AGARWAL				
	At the beginning of the year 01-Apr-2020	32000	0.3807	32000	0.3807
	BONUS	3555	0.0355	35555	0.3553
	At the end of the Year 31-Mar-2021	35555	0.3553	35555	0.3553
8	MANISH MITTAL HUF				
	At the beginning of the year 01-Apr-2020	36000	0.4283	36000	0.4283
	Sale 31-Jul-2020	-4000	0.0399	32000	0.3198
	Sale 28-Aug-2020	-4000	0.0399	28000	0.2798
	Sale 03-Sep-2020	-8000	0.0799	20000	0.1998
	Sale 11-Sep-2020	-20000	0.1998	0	0.0000
	At the end of the Year 31-Mar-2021	0	0.0000	0	0.0000
9	SUNIL KUMAR RANA .				
	At the beginning of the year 01-Apr-2020	32000	0.3807	32000	0.3807
	Sale 24-Apr-2020	-8000	0.0799	24000	0.2398
	Sale 09-Oct-2020	-16000	0.1599	8000	0.0799
	Purchase 23-Oct-2020	12000	0.1199	20000	0.1998
	Sale 30-Oct-2020	-8000	0.0799	12000	0.1199
	Sale 06-Nov-2020	-12000	0.1199	0	0.0000
	Purchase 27-Nov-2020	8000	0.0799	8000	0.0799
	Sale 04-Dec-2020	-8000	0.0799	0	0.0000
	At the end of the Year 31-Mar-2021	0	0.0000	0	0.0000
10	ANIL KUMAR GUPTA .				
	At the beginning of the year 01-Apr-2020	32000	0.3807	32000	0.3807
	Sale 21-Aug-2020	-32000	0.3198	0	0.0000

	At the end of the Year 31-Mar-2021	0	0.0000	0	0.0000
	NEW TOP 10 AS ON (31-Mar-2021)				
11	DAYAL TAHILRAM PARWANI				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 19-Mar-2021	106656	1.0659	106656	1.0659
	Purchase 26-Mar-2021	79992	0.7994	186648	1.8654
	Purchase 31-Mar-2021	8888	0.0888	195536	1.9542
	At the end of the Year 31-Mar-2021	195536	1.9542	195536	1.9542
12	PRITAM KAUR				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 31-Jul-2020	12000	0.1199	12000	0.1199
	Purchase 14-Aug-2020	12000	0.1199	24000	0.2398
	Purchase 21-Aug-2020	27403	0.2738	51403	0.5137
	Sale 28-Aug-2020	-3403	0.0340	48000	0.4797
	Purchase 11-Sep-2020	32000	0.3198	80000	0.7995
	Purchase 18-Sep-2020	24000	0.2398	104000	1.0394
	Purchase 25-Sep-2020	8000	0.0799	112000	1.1193
	Purchase 11-Dec-2020	32000	0.3198	144000	1.4391
	Purchase 18-Dec-2020	4000	0.0399	148000	1.4791
	BONUS	16444	0.1643	164444	1.6435
	At the end of the Year 31-Mar-2021	164444	1.6435	164444	1.6435
13	PRITIKA INDUSTRIES LTD				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 16-Oct-2020	24000	0.2398	24000	0.2398
	Purchase 06-Nov-2020	48000	0.4797	72000	0.7195
	Purchase 20-Nov-2020	12000	0.1199	84000	0.8395
	Purchase 04-Dec-2020	20000	0.1998	104000	1.0394
	BONUS	11555	0.1154	115555	1.1549
	At the end of the Year 31-Mar-2021	115555	1.1549	115555	1.1549
14	VALUEWORTH ADVISORS LLP				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 26-Feb-2021	100000	0.9994	100000	0.9994
	BONUS	11111	0.1110	111111	1.1104
	At the end of the Year 31-Mar-2021	111111	1.1104	111111	1.1104
15	RAJSHREE MOHTA				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 28-Aug-2020	12000	0.1199	12000	0.1199
	Purchase 03-Sep-2020	44000	0.4397	56000	0.5596
	Purchase 11-Sep-2020	8000	0.0799	64000	0.6396
	BONUS	7111	0.0710	71111	0.7107
	At the end of the Year 31-Mar-2021	71111	0.7107	71111	0.7107

16	LALIT AGGARWAL				
	At the beginning of the year 01-Apr-2020	0	0.0000	0	0.0000
	Purchase 21-Aug-2020	16000	0.1599	16000	0.1599
	Purchase 09-Oct-2020	20000	0.1998	36000	0.3597
	Purchase 16-Oct-2020	20000	0.1998	56000	0.5596
	BONUS	6222	0.0621	62222	0.6218
	At the end of the Year 31-Mar-2021	62222	0.6218	62222	0.6218

v) SHAREHOLDING OF DIRECTORS & KEY MANAGERIAL PERSONNEL:

Sr. No	Director's, KMP / Shareholder's Name	Shareholding at the beginning of the year (01.04.2020)			Shareholding at the end of the year (31.03.2021)			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Jasjot Singh	702050	8.35	0	1686720	16.85	0	+9.84
2.	Partek Singh	0	0	0	0	0	0	0
3.	Gursimran Singh	64000	0.76	0	22222	0.22	0	-0.54

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	3,84,83,886	1,17,69,440	-	5,02,53,326
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not	-	-	-	-
Total(i+ii+iii)	3,84,83,886	1,17,69,440	-	5,02,53,326
Change in Indebtedness during the financial year				
- Addition	2,85,52,687	0		2,85,52,687
- Reduction	0	(1,09,69,440)		(1,09,69,440)
Net Change	2,85,52,687	(1,09,69,440)	-	1,75,83,247
Indebtedness at the end of the financial year				
i) Principal Amount	6,70,36,573	8,00,000	-	6,78,36,573
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	6,70,36,573	8,00,000		6,78,36,573

VI. REMUNERATION OF DIRECTORS AND KEYMANAGERIAL PERSONNEL
A. REMUNERATION TO MANAGING DIRECTOR, WHOLE-TIME DIRECTORS AND/OR MANAGER

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount (Rs.)
	Gross salary (Rupees)	Jasjot Singh (MD)	Partek Singh (Director)	Gursimran Singh (Ex. Director-w.e.f. 13/08/2020)	Dr. Rajesh Parashar (Ex. Director-upto 13/08/2020)	
	(a)Salary as per provisions contained in section17(1) of the Income-tax Act, 1961	18,00,000	3,00,000	5,40,000	2,00,000	28,40,000
	(b)Value of perquisites u/s 17(2)Income-tax Act, 1961	NIL	NIL	NIL	NIL	NIL
	(c)Profits in lieu of salary under section 17(3) Income taxAct,1961	NIL	NIL	NIL	NIL	NIL
	Stock Option	NIL	NIL	NIL	NIL	NIL
	Sweat Equity	NIL	NIL	NIL	NIL	NIL
	Commission - as % of profit - others, specify...	NIL	NIL	NIL	NIL	NIL
	Others, please specify (Sitting Fees)	NIL	NIL	NIL	NIL	NIL
	Total(A)	18,00,000	3,00,000	5,40,000	2,00,000	28,40,000

B. REMUNERATION TO OTHER DIRECTORS:

Particulars of Remuneration (Rs.)	Mr. Imteshwar Singh	Mr. Ramandeep Singh	Ms. Simmi Chhabra	Total Amount (Rs.)
<u>Independent Directors</u> ·Fee for attending board committee meetings ·Commission ·Others, please specify	27,000	27,000	27,000	81,000
Total(1)	NIL	NIL	NIL	NIL
<u>Other Non-Executive Directors</u> ·Fee for attending board committee meetings ·Commission ·Others, please specify	-	-	-	-
Total(2)	-	-	-	-
Total(B)=(1+2)	27,000	27,000	27,000	81,000
Total Managerial Remuneration	NIL	NIL	NIL	NIL
Overall Ceiling as per the Act (1% of the Net Profits of the Company)				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD.

Sl no.	Particulars of Remuneration	Key Managerial Personnel		Total (Rs.)
		Ms. Swati Vijan (CS)	Mr. Gurmeet Singh (CFO)	
1.	Gross salary (a)Salary as per provisions contained in section17(1)of the	5,71,000	12,00,000	17,71,000

	Income-tax Act,1961			
	(b)Value of perquisites u/s 17(2)Income-tax Act,1961	0.00	0.00	0.00
	(c)Profits in lieu of salary under section 17(3) Income -tax Act,1961	0.00	0.00	0.00
2.	Stock Option	0.00 0.00	0.00	0.00
3.	Sweat Equity	0.00 0.00	0.00	0.00
4.	Commission - as % of profit - others, specify	0.00 0.00	0.00	0.00
5.	Others, please specify	0.00 0.00	0.00	0.00
6.	Total	5,71,000	12,00,000	17,71,000

VII. PENALTIES/PUNISHMENT/COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	Nil	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil	Nil
Compounding	Nil	Nil	Nil	Nil	Nil
B. DIRECTORS					
Penalty	Nil	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil	Nil
Compounding	Nil	Nil	Nil	Nil	Nil
C. OTHER OFFICERS IN DEFAULT					
Penalty	Nil	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil	Nil
Compounding	Nil	Nil	Nil	Nil	Nil

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021
Place: Mohali

Jasjot Singh
Managing Director
DIN: 01937631

Gursimran Singh
Director
DIN: 02209675

ANNEXURE 'B' TO DIRECTORS' REPORT

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
1	Name (s) of the related party & nature of relationship	NIL
2	Nature of contracts/arrangements/transaction	NIL
3	Duration of the contracts/arrangements/transaction	NIL
4	Salient terms of the contracts or arrangements or transaction including the value, if any	NIL
5	Justification for entering into such contracts or arrangements or transactions'	NIL
6	Date of approval by the Board	NIL
7	Amount paid as advances, if any	NIL
8	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	NIL

2. Details of contracts or arrangements or transactions at Arm's length basis.

S. No.	Name of the related party and nature of relationship	Nature of contracts/arrangements/transactions	Duration of the contracts/arrangements/transactions	Salient terms of the Contracts or arrangements or transactions including the value, if any	Date(s) of Approval by the board	Amount paid as Advances, if any.
1.	Healthy Biosciences Private Limited	1. Purchases 2. Rent Paid	Transactions in normal course of business.	Purchases: Rs. 34,00,610.00/- Rent paid: Rs. 2,12,400.00/-	02.04.2020	-
2.	Prism Medico & Pharmacy Limited	1.Purchases	Transactions in normal course of business.	Purchases: Rs. 9,13,050.00/-	02.04.2020	-

ANNEXURE 'C' TO DIRECTORS' REPORT

Information pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

PARTICULARS OF EMPLOYEES PURSUANT TO SECTION 134(3)(q) OF THE COMPANIES ACT, 2013 READ WITH RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- (i) The ratio of the remuneration of each Executive Director to the median remuneration of the employees of the Company for the financial year 2020-21 along with the percentage increase in Remuneration of each Executive Director and Key Managerial Personnel (KMP) during the financial year 2020-21:

Sr. No.	Name of Director and KMP	Designation	Ratio of remuneration of each Director / KMP to the Median Remuneration of Employees	Percentage increase in Remuneration during the financial year
1.	Mr. Jasjot Singh	Managing Director	15.7 : 1	16.6%
2.	Mr. Partek Singh	Director	2.6 : 1	-
3.	Mr. Gursimran Singh	Director	9.4 : 1	-
4.	Mr. Gurmeet Singh	Chief Financial Officer	10.5 : 1	-
5.	Ms. Swati Vijan	Company Secretary/ Compliance Officer	4.82 : 1	-

Notes:

- a) The Independent Directors of the Company are entitled to sitting fee and commission on Net Profits as per statutory provisions of the Companies Act, 2013 and as per terms approved by the Members of the Company.
b) Percentage increase in remuneration indicates annual total compensation increase, as recommended by the Nomination and Remuneration Committee and duly approved by the Board of Directors of the Company.
c) Employees for the purpose above include all employees excluding employees governed under collective bargaining process.

(ii) There were 47 permanent employees on the rolls of the Company as on March 31, 2021.

(iii) It is hereby affirmed that the remuneration paid to all the Directors, KMP, Senior Managerial Personnel and all other employees of the Company during the financial year ended March 31, 2021, were as per the Nomination and Remuneration Policy of the Company.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021

Place: Mohali

Jasjot Singh
Managing Director
DIN: 01937631

Gursimran Singh
Director
DIN: 02209675

ANNEXURE 'D' TO DIRECTORS' REPORT

CORPORATE GOVERNANCE REPORT**(1) COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE**

The Company's philosophy on Corporate Governance has been developed with a tradition of fair and transparent governance. Transparency, integrity, professionalism and accountability based values form the basis of the Company's philosophy for Corporate Governance and the continued application of these principles to the business practices has led to the growth of the Company over the years. The Company believes that corporate governance is beyond financial results and is a pre-requisite to the attainment of excellent performance in terms of stakeholders' long term value creation. The Company believes Corporate Governance is an ethically driven business process that is committed to values, aimed at enhancing an organization's brand and reputation. Hence, it is imperative to establish, adopt and follow best corporate governance practices, there by facilitating effective management and carrying out our business by setting principles, benchmarks and systems to be followed by the Board of Directors (the "Board"), Management and all Employees in their dealings with Customers, Stakeholders and Society at large.

The objective of the Company is not only to achieve excellence in Corporate Governance by conforming to prevalent mandatory guidelines on Corporate Governance but also to improve on these aspects on an ongoing basis with a continuous attempt to innovate in adoption of best business practices for value creation. The Company believes that good Corporate Governance is a continuous improvement seeking process and strives to further improve the Corporate Governance practices to meet the expectations of all the stakeholders.

We detail hereunder the Company's compliance with Regulation 34(3) read with Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "SEBI Listing Regulations"):

(2) THE BOARD OF DIRECTORS

The Board is at the core of our corporate governance practice and oversees how the Management serves and protects the long-term interests of our stakeholders. We believe that an active, well-informed and independent Board is necessary to ensure the highest standards of corporate governance.

a) Size and Composition of Board

The composition of the Board is in conformity with Section 149 of the Companies Act, 2013 and Regulation 17 of the SEBI (LODR) Regulations 2015, which stipulates that the Board should have optimum combination of executive and non-executive directors with at least one Independent woman director and at least 50% of the Board should consist of independent directors, as the Chairman of our Board is an executive director.

As on 31st March, 2021 the Board is comprised of 6 (Six) Directors. Out of these:

- Three are Executive Directors including one Managing Director who is also the promoter of the company and remaining two are Executive Directors.
- Three are Non- Executive Directors and all three are Independent Directors out of which one is Women Director.

All the Independent Directors satisfy the criteria of independence as as required under Section 149 of the Companies Act, 2013 read with schedule IV of the Companies Act, 2013.

None of the Directors of the Company are related to each other.

b) Number of Board Meetings

Minimum four prescheduled Board meetings are held every year. Additional meetings are held by giving appropriate notice to address specific needs of the company.

During the Financial Year 2020-21, the Board of Directors met 9 (nine) times during the year on 02.04.2020, 29.06.2020, 13.08.2020, 07.09.2020, 05.11.2020, 10.11.2020, 23.01.2021, 01.03.2021 and 13.03.2021. The maximum time gap between two consecutive meetings did not exceed one hundred and twenty days.

Meeting of the Board of Directors which was to be held on 15/01/2021 was adjourned and held on 23/01/2021.

c) Attendance of Directors at the Board Meetings, Committee Meetings and Last AGM

In terms of SEBI Listing Regulations, none of the Directors are members of more than 10 Board level committees, nor are they Chairman of more than five committees in which they are members. Further, none of the Directors of the Company serve as an Independent Director in any other company except Mrs. Simmi Chhabra, who who is appointed as an Independent Director in another listed company also.

Following is the attendance of Directors at the Board Meetings held during the year and at the last Annual General Meeting and also the number of Directorships and Board-level committee positions held by them:

Name of Director	Category of Directorship	DIN	Attendance Particulars			No. of other Companies Directorships and Committee memberships/ chairmanships of the company*		
			No. of Board Meetings attended	Last AGM	Other Directorships	Committee Memberships	Committee Chairmanships	
			Held	Attended				
Mr. Jasjot Singh	ED –MD	01937631	09	09	Yes	1	--	--
Mr. Gursimran Singh	ED	02209675	06	06	Yes	1	--	-
Mr. Partek Singh	ED	07864006	09	09	Yes	--	--	--
Mr. Ramandeep Singh	NED –ID	07896086	09	08	Yes	--	3	--
Mr. Imteshwar Singh	NED –ID	07864007	09	09	Yes	--	3	--
Mrs. Simmi Chhabra	NED –ID	07870398	09	09	Yes	2	3	3
Dr. Rajesh Parashar	ED		02	01	N.A.	--	--	--

*ED stands for Executive Director; MD stands for Managing Director; WTD stands for Whole-Time Director, NED stands for Non- Executive Director and ID stands for Independent Director.

Note: None of the Directors of the Company are on the Board of any other listed entity except Mrs. Simmi Chhabra who is appointed as an Independent Director in Prism Medico & Pharmacy Limited, company which is listed on BSE and MSEI.

d) Disclosure of relationships between directors inter-se

None of the other Directors are related to each other in any manner.

e) Shareholding of Non-Executive Directors:

As on 31st March 2021, shareholding of the non-executive directors is as below:

Name of Director	Category	No. of shares held (Rs 10/- paid up)
Simmi Chhabra	NED-ID	17777
Imtishwar Singh Bhatia	NED-ID	-
Ramadeep Singh	NED-ID	-

f) Details of familiarization programmes imparted to independent directors

Pursuant to the Code of Conduct for Independent Directors specified under the Companies Act, 2013 and requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has framed a familiarization programme for all its Independent Directors to familiarize them on their roles, rights and responsibilities in the Company.

The Familiarization programme for Independent Directors is posted on the website at <https://ajoonibiotech.com/> and the direct link to the programme is at https://ajoonibiotech.com/Uploads/Policy/familiarisation_programme.pdf.

g) Confirmation on Independent Directors

The Board based on the disclosures received from all Independent Directors, confirms that all Independent Directors fulfil the conditions of Independence as specified in SEBI Listing Regulations and are independent of the management of the Company for the year ended March 31, 2020.

h) Resignation of Independent Directors

During the year, none of the Directors resigned from the Board of Directors.

i) Role of Board Members:

The Board of Directors of the Company directs the Company by formulating and reviewing Company's policies, strategies and business plans. The Board of the Company provides leadership and strategic guidance to the Company and exercises control over the Company, while remaining at all times accountable to the shareholders.

The Board of Directors of the Company is constituted in compliance with the Corporate Governance principles. As on the date of adoption of Corporate Governance Report, the Board is having Six members with Mr. Jasjot Singh Chairing the Board.

The Company has not entered into any other materially significant transaction with its Directors/Management or relatives etc. affecting the interest of the Company at large except in normal course of business.

j) Procedure of the Board Meetings:

The meetings of the Board are convened by giving appropriate advance notice to the members of the Board and to Stock Exchange.

The Compliance officer of the Company circulates internal notice to all the Board members and division heads asking for the suggestions/ details of any matter which requires discussion or approval of the Board so that the same could be incorporated in the agenda of the Board meeting. The date of the Board meeting is fixed taking into account convenience and availability of the Board members.

The Board of the Company is presented with all the relevant information on various vital matters affecting the working of the Company as well as those matters, which require deliberation at the highest level. Board Members are given appropriate documents / detailed notes and information in advance of each Board and Committee Meeting. The minutes of the Committee of Board of Directors are taken as read at the meeting of Board for information of the members. The follow up actions of important agenda items of previous Board meeting are placed at the Board meeting for review of the Board.

The Compliance officer of the Company conducts the Board meetings and prepares all documents including minutes of the meeting in compliance with the provisions of the Companies Act and other statutory enactments.

(3) REMUNERATION TO DIRECTORS

Directors with pecuniary relationship or business transactions with the Company

The Managing Director of the Company receive Salary, Perquisites, Allowances, commission on net profits and other benefits as stated in the agreements entered into between the Company and MD as the case may be, while all the Non-Executive Directors receive Sitting Fees. It is to be noted that the transactions with other entities where Directors are interested are being carried out at an arm's length and in compliance with the laws applicable thereto. There are no pecuniary transactions/relationships of the Company with Non-Executive Directors except sitting fees and reimbursement of expenses for attending meetings.

Criteria of making payments to non-executive directors

The Non-Executive/Independent Directors of the Company bring with them significant professional expertise and rich experience across the wide spectrum of functional areas such as marketing, legal, finance and other corporate and management functions.

The Non-Executive and Independent directors are paid sitting fees for attending Board and Committee meetings and expenditure incurred for such attendance is reimbursed. No other fee, remuneration, etc. is being paid to them

Remuneration to Directors

The appointment and remuneration of Executive Directors including Managing Director, is governed by the recommendation of the Nomination and Remuneration Committee, resolutions passed by the Board of Directors and Shareholders of the Company. Any annual pay, variable pay or incentives, if any, payable to Executive Directors is approved by the Board based on recommendation from Nomination and Remuneration Committee. The Non-Executive and Independent directors are paid sitting fees for attending Board and

Committee meetings and expenditure incurred for such attendance is reimbursed. No other fee, remuneration, etc. is being paid to them.

(Amount in Rs. Lakhs)

Name of the Director	Salaries, perquisites and allowances	Commission	Sitting fees	Total
Mr. Jasjot Singh	18.00	-	-	18.00
Mr. Gursimran Singh	5.40	-	-	5.40
Mr. Partek Singh	3.00	-	-	3.00
Mr. Ramandeep Singh	-	-	0.27	0.27
Mr. Imtेशwar Singh	-	-	0.27	0.27
Mrs. Simmi Chhabra	-	-	0.27	0.27
Total	26.40	-	0.81	27.21

Service Contracts, Notice Period and Severance fees:

As at March 31, 2021, the Board comprised of six directors including three executive directors and three non-executive directors and independent directors. The Company has entered into agreements with Mr. Jasjot Singh, Managing Director which inter alia stipulate a three months' notice period to vacate their respective office held. There is no provision for payment of severance fees. The other Non-Executive Directors and Independent Directors are not subject to any specific requirement of notice period and severance fees.

Stock Option details

During the year, no stock options were granted to any executive / non-executive director of the Company.

COMMITTEES OF THE BOARD

Currently, the Board has three committees: Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee

(4) AUDIT COMMITTEE

The scope of activities of the Audit Committee is set out as per SEBI (LODR) Regulations 2015 read with Section 177 of the Companies Act, 2013.

The terms of reference and powers of the Audit Committee are in conformity with the requirements of Regulation 18 of SEBI Listing Regulations and Section 177(1) of the Companies Act, 2013. Powers of the Committee and its terms of reference are as under:

1. Oversight of the company's financial reporting process.
2. the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
3. Recommendation for appointment, remuneration and terms of appointment of auditors of the company;
4. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
5. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of section 134 of the Companies Act, 2013.
 - Changes, if any, in accounting policies and practices and reasons for the same

- Major accounting entries involving estimates based on the exercise of judgment by management
 - Significant adjustments made in the financial statements arising out of audit findings
 - Compliance with listing and other legal requirements relating to financial statements
 - Disclosure of any related party transactions
 - Qualifications in the draft audit report
6. Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
 7. Reviewing, with the management, the statement of uses / application of funds raised through and issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
 8. Review and monitor the auditor's independence and performance, and effectiveness of audit process;
 9. Approval or any subsequent modification of transactions of the company with related parties;
 10. Scrutiny of inter-corporate loans and investments;
 11. Valuation of undertakings or assets of the company, wherever it is necessary;
 12. Evaluation of internal financial controls and risk management systems;
 13. Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
 14. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
 15. Discussion with internal auditors of any significant findings and follow up there on;
 16. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
 17. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post audit discussion to ascertain any area of concern;
 18. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
 19. To review the functioning of the Whistle Blower mechanism;
 20. Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
 21. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee.

As on 31st March 2021, the Audit committee comprised of three Directors and all the members are independent directors.

During the Financial Year 2020-21, The Audit Committee met 5 times during the year on 02.04.2020, 29.06.2020, 13.08.2020, 10.11.2020 and 13.03.2021.

The details of the composition of the Committee and attendance at the meetings are given below:

S. No.	Name of Director	Category	Designation	No. of Board Meetings attended	
				Held	Attended
1	Mrs. Simmi Chhabra	NED- ID	Chairperson	5	5
2	Mr. Ramandeep Singh	NED- ID	Member	5	5
3	Mr. Imtешwar Singh	NED- ID	Member	5	5

***NED stands for Non- Executive Director and ID stands for Independent Director.**

(5) NOMINATION AND REMUNERATION COMMITTEE

In accordance with Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI Listing Regulations, the role of the Nomination and Remuneration Committee of the Company is as under:

1. To formulate criteria for determining qualifications, positive attributes and independence of Directors.
2. Formulate criteria for evaluation of Independent Directors and the Board.
3. Identify persons who are qualified to become Directors and individuals who may be appointed in Senior
4. Management positions in accordance with the criteria laid down by the Committee.
5. To carry out evaluation of every Director's performance.
6. To recommend to the Board, the appointment and removal of Directors and Senior Management.
7. To recommend to the Board, policy relating to remuneration for Directors, Key Managerial Personnel and Senior Management.
8. Ensure that level and composition of remuneration is reasonable and sufficient, relationship of remuneration to performance is clear and meets appropriate performance benchmarks.
9. To devise a policy on Board diversity.
10. To carry out any other function as is mandated by the Board from time to time and/or as required under any statutory notification, amendment or modification, as may be applicable.
11. To determine the extension or continuation of term of Independent Directors on the basis of the report of their performance evaluation.
12. To perform such other functions as may be necessary or appropriate for the performance of such duties.

As on 31st March 2021, the Nomination & Remuneration committee comprised of three Directors and all the members them are independent directors.

During the Financial Year 2020-21, The Nomination & Remuneration committee met 2 times during the year on 13.08.2020 and 07.02.2021.

The details of the composition of the Committee, and attendance at the meetings are given below:

S. No.	Name of Director	Category	Designation	No. of Board Meetings attended	
				Held	Attended
1	Mrs. Simmi Chhabra	NED- ID	Chairperson	2	2
2	Mr. Ramandeep Singh	NED- ID	Member	2	2
3	Mr. Imtешwar Singh	NED- ID	Member	2	2

***NED stands for Non- Executive Director and ID stands for Independent Director.**

INDEPENDENT DIRECTORS' MEETING

During the year under review, the Independent Directors met on February 25, 2021, inter alia, to discuss:

- Evaluation of the performance of Non Independent Directors and the Board of Directors as a whole;
- Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive and Non-Executive Directors;

- Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

The details of the attendance of the Independent Directors at the meeting are given below. No sitting fee was paid for the said meeting.

S. No.	Name of Director	Category	Designation	No. of Board Meetings attended	
				Held	Attended
1	Mrs. Simmi Chhabra	NED- ID	Chairperson	1	1
2	Mr. Ramandeep Singh	NED- ID	Member	1	1
3	Mr. Imteshwar Singh	NED- ID	Member	1	1

(6) STAKEHOLDERS' GRIEVANCE COMMITTEE

The terms of reference of the Committee are as follows:

1. To supervise and ensure efficient share transfers, share transmission, transposition, etc.;
2. To approve allotment, transfer, transmission, transposition, consolidation, split, name deletion and issue of duplicate share certificates for equity shares of the Company;
3. To redress shareholders' complaints like non-receipt of balance sheet, non-receipt of declared dividends, etc.;
4. To review service standards and investor service initiatives undertaken by the Company;
5. To place before the Board meeting, a quarterly report giving details such as number of complaints received, resolved, pending during the quarter;
6. To report immediately to the Board, specific grievance raised by the shareholders/investors which could not be resolved by the committee and which need immediate attention;
7. To address all matters pertaining to Registrar and Transfer Agent including appointment of new Registrar and Transfer Agent in place of existing one;
8. To address all matters pertaining to Depositories for dematerialization of shares of the Company and other matters connected therewith; and
9. To attend to any other responsibility as may be entrusted by the Board or investigate any activity within terms of its reference.

As on 31st March 2021, the Stakeholders' grievance committee comprised of three Directors and all the members them are independent directors.

During the Financial Year 2020-21, The Stakeholders' grievance committee met 2 times during the year on 07.09.2020 and 07.01.2021.

The details of the composition of the Committee, and attendance at the meetings are given below:

S. No.	Name of Director	Category	Designation	No. of Board Meetings attended	
				Held	Attended
1	Mrs. Simmi Chhabra	NED- ID	Chairperson	2	2
2	Mr. Ramandeep Singh	NED- ID	Member	2	2
3	Mr. Imteshwar Singh	NED- ID	Member	2	2

*NED stands for Non- Executive Director and ID stands for Independent Director.

Details of Shareholders' complaints

Details of complaints received, resolved and pending as on March 31, 2021 are as under:

Pending as on April 1, 2020	Complaints Received during the year	Complaints Resolved during the year	Pending as on March 31, 2021
Nil	Nil	Nil	Nil

(7) SHAREHOLDERS INFORMATION

General Body Meetings

Particulars of General Meetings held in last three years:

AGM/EGM	Financial Year	Venue	Day & Date	Time	No. of Special Resolution passed
10 th AGM	2019-20	Plot No. D-118, Industrial Area, Phase 7, Mohali, Punjab-160055 through VIDEO CONFERENCING ('VC')/ OTHER AUDIO VISUAL MEANS (OAVM)	Thursday, the 10 th Day of September, 2020	10.000 AM	6
9 th AGM	2018-19	MOHALI INDUSTRIES ASSOCIATION, BAY NO.143-144, INDUSTRIAL AREA PHASE VII, MOHALI-160055	Monday, the 30 th Day of September, 2019	09.00 AM	10
8 th AGM	2017-18	MOHALI INDUSTRIES ASSOCIATION, BAY NO.143-144, INDUSTRIAL AREA PHASE VII, MOHALI-160055	Friday, the 28 th Day of September, 2018	04.00 PM	4

Postal Ballot

During the F.Y. 2017-18,2018-19 and 2019-20, no resolution was passed through postal ballot process. No resolution is proposed to be passed through postal ballot.

Further, During the F.Y. 2020-21, three resolutions were passed through postal ballot vide notice dated 23rd January 2021.

(8) MEANS OF COMMUNICATION

In accordance with Regulation 46 of SEBI Listing Regulations, the Company has maintained a functional website at www.ajoonibiotech.com containing basic information about the Company viz., details of its

business, financial information, shareholding pattern, compliance with corporate governance, contact information of the designated officials of the Company who are responsible for assisting and handling investor grievances, etc. The contents of the said website are updated as and when required. The results along with presentations made by the Company to Analysts are also filed with the Exchanges and hosted on the website of the Company.

Further, the Company disseminates to the Stock Exchange, wherein its equity shares are listed, all mandatory information and price sensitive/such other information, which in its opinion, are material and/or have a bearing on its performance/operations and issues press releases, wherever necessary, for the information of the public at large.

(9) GENERAL SHAREHOLDERS' INFORMATION

- **Annual General Meeting proposed to be Held**

Day, Date & Time : Monday, 27th Day of September 2021 at 10.30 A.M.
 Venue : Plot No. D-118, Industrial Area Phase 7, Mohali, Punjab-160055

- **Financial year** : 1st April 2020 to 31st March 2021

- **Dividend Payment date**

No final dividend for FY 2020-21 is proposed by the Board.

- **Financial Calendar 2021-22 (Tentative)**

Results for the quarter ended 30 th June, 2021	By 14 th August, 2021
Results for the quarter ended 30 th Sep, 2021	By 14 th November, 2021
Results for the quarter ended 31 th Dec, 2021	By 14 th February, 2022
Results for the quarter ended 31 st March, 2022	By 30 th May, 2022

- **Listing**

The Equity Shares of the Company are listed on National Stock Exchange of India Limited (NSE), Exchange Plaza, Bandra – Kurla Complex, Bandra (East), Mumbai- 400 051.

The Company has paid the annual listing fees for the year 2019-20 to NSE.

- **Stock Code**

ISIN : INE820Y01013
 SYMBOL : AJOONI

- **Book Closure Dates:** Tuesday, 21stSeptember 2021 to Monday, 27thSeptember 2021 (Both days inclusive)

- **STOCK DATA**

Table below gives the monthly high and low prices and volumes of trading of Equity Shares of the Company at National Stock Exchange of India Limited (NSE) for the year 2020-21.

(Face Value Rs. 10/- per share)

NATIONAL STOCK EXCHANGE OF INDIA LIMITED			
Month & Year	High	Low	Traded Volume (In Lakhs)
April, 2020	7.35	6.75	0.24

May, 2020	7.00	6.35	0.16
June, 2020	8.30	6.65	1.36
July, 2020	18.25	7.90	4.32
August, 2020	36.50	17.25	15.40
September, 2020	36.00	29.50	6.08
October, 2020	35.00	33.00	5.12
November, 2020	33.60	30.35	1.68
December, 2020	33.50	28.50	2.72
January, 2021	34.70	29.15	6.96
February, 2021	33.45	29.80	5.16
March, 2021	32.00	29.60	3.70

• **Distribution of shareholding as at 31.03.2021:**

Distribution of shareholding of the equity shares of the company by size and ownership class as on 31.03.2021 is as under:

(a) Shareholding pattern by size:

Shares holding Nominal Value of (Rs.)	No. of Shareholders	% to Total Numbers	Share holding Amount (Rs.)	% to Total Amount
1	2	3	4	5
10 To 5,000	3	1.094	2010	0.0020
5001 To 10,000	0	0	0	0
10001 To 20,000	1	0.364	10810	0.010
20001 To 30,000	0	0	0	0
30001 To 40,000	1	0.364	40000	0.039
40001 To 50,000	171	62.408	7599240	7.595
50001 To 1,00,000	45	16.423	3993240	3.991
1,00,000 and Above	53	19.343	88410520	88.361
Total	274	100	100055820	100

(b) Shareholding Pattern by ownership:

Category	No. of Shares held	Voting Strength (%)
Promoters Holding	5166688	51.64
Non-Promoter Holding	4838894	48.36

• **Registrar and Share Transfer Agents**

Cameo Corporate Services Limited,
Subramaniam Building No. 1, Club House Road, Chennai-600002.
E-mail: sofia@cameoindia.com. cameosys@cameoindia.com

• **Share Transfer System**

The Registrars and Share Transfer Agents have put in place an appropriate Share Transfer system to ensure timely share transfers. Share Transfers are registered and returned in the normal course within an average

period of 15 days from the date of receipt, if the documents are clear in all respects. Requests for dematerialization of shares are processed and confirmation is given to the respective depositories i.e. NSDL and CDSL within 21 days.

There are no shares in demat suspense account or unclaimed suspense account as on March 31, 2020.

- **Dematerialization of shares and liquidity**

The Equity Shares of the Company have been admitted by both depositories namely, NSDL and CDSL.

As on 31st March, 2021, 10005582 equity shares representing 100% of the company’s total paid up capital have been dematerialized.

Category	Number of shareholders	Total shares	Percentage
Physical	0	0	0
N S D L	130	6163261	61.60
C D S L	144	3842321	38.40
Total	277	10005582	100

- **Outstanding Instruments**

There are no outstanding Global Depository Receipts / American Depository Receipts / warrants / any convertible instruments.

- **Commodity price risk or foreign exchange risk and hedging activities:**

The Company had no such transactions during the year hence the Company has not opted for hedging. Details of foreign currency exposure, where applicable are disclosed in notes to the financial statements. As such no disclosure is warranted in terms of SEBI circular SEBI/HO/CFD/CMD1/CIR/P/2018/0000000141 dated November 15, 2018.

- **Compliance Officer**

Ms. Swati Vijan, Company Secretary of the company is designated as a Compliance Officer of the company, who can be reached at: AJOONI BIOTECH LIMITED at Registered Address: D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 or at Email id- ajooni118@gmail.com / cs@ajoonibiotech.com.

- **Registered office and Plant Locations**

- I) PLOT NO. D-118, INDUSTRIAL AREA, PHASE 7, MOHALI, PUNJAB-160055
- II) GT ROAD, KHANNA, DIST. LUDHIANA, PUNJAB

- **Address for Correspondences**

PLOT NO. D-118, INDUSTRIAL AREA, PHASE 7, MOHALI, PUNJAB-160055

(10) AFFIRMATIONS AND DISCLOSURES

- **Compliances with Governance Framework**

The Company is in compliance with all mandatory requirements under the SEBI Listing Regulations.

- **Related Party Transactions**

Details of related party transactions are presented as part of the Notes to the Financial Statements. All details on the financial and commercial transactions, where Directors may have a potential interest, are provided to the Board. The interested Directors neither participate in the discussion, nor vote on such matters.

During the financial year, no materially significant related party transactions, that may have potential conflict with the interests of the Company at large, have been entered into by the Company. All transactions entered into with the Related Parties as defined under Companies Act, 2013 during the year were in the ordinary course of business and on an arm’s length basis, and did not attract provisions of Section 188 of Companies Act, 2013, relating to approval of shareholders. Omnibus approval from the Audit Committee was obtained for all transactions which are repetitive and normal in nature. All transactions with Related Parties were entered into with prior approval of Audit Committee as well as the Board and ratified by the Audit Committee once the transactions took place. Further, disclosures are made to the Committee and the Board on a quarterly basis.

Company has adopted a Related Party Transactions Policy which is available on the website of the Company i.e. <https://ajoonibiotech.com/Uploads/Policy/RELATED%20PARTY%20TRANSACTION%20POLICY.pdf>

- **Non-compliance, penalties, strictures imposed on the Company**

The Company is in compliance with the requirements of the Stock Exchanges or SEBI or any other statutory authority on all matters related to capital markets, since listing on the Stock Exchanges. Further, there were no non-compliances, or penalties, or strictures imposed on the Company as mentioned below.

There has been no disciplinary action by other stock exchanges and regulatory authorities in past three years except SOP fine levied by National Stock Exchange to the Company under SEBI ICDR/LODR Regulations. The same has already paid as per the requirements. i.e.

NSE Reference Letter No.	Non-Compliance Provision	Fine Amount (Rs.)	Amount Paid (Rs.)
NSE/LIST-SOP/REG-29/FINES/100856 dated September 10, 2020	Regulation 29 (2)/ (3) of SEBI (LODR) Regulations, 2015	Rs. 11,800 (including GST)	Amount paid- Rs. 11050 TDS deducted – Rs. 750 UTR No.- P20091445695139 dated 14/09/2020
NSE/LIST/102902 DATED March 02, 2020	Non compliance of provisions of SEBI (ICDR) Regulations 2018	RS. 47,200 (including GST)	Amount paid- Rs. 47,200 UTR No.- P20030488263548 dated 04/03/2020

- **Details of establishment of vigil mechanism, whistle blower policy and affirmation that no personnel has been denied access to the audit committee**

The Company has implemented the vigil mechanism policy to report genuine concerns. The policy provides for adequate safeguards against victimization of persons who use such mechanism and makes provision for direct access to the chairperson of the audit committee in appropriate or exceptional cases.

During the year, none of such personnel have been denied access to the audit committee. The whistle blower policy of the Company can be accessed through the following link. https://ajoonibiotech.com/Uploads/Policy/whistle_blower_policy.pdf.

- **Details of compliances with mandatory requirements of corporate governance and adoption of non-mandatory requirements**

All mandatory requirements of corporate governance have been complied with. Details of compliance with non-mandatory requirements or discretionary requirements as required under Part E of Schedule II are provided as above.

- **Compliance with Secretarial Standards**

The Institute of Company Secretaries of India issued Secretarial Standards for Board and General Meetings in exercise of powers under Section 118 of the Companies Act, 2013. The Company complies with all requirements of said Secretarial Standards.

- **Accounting treatment in preparation of financial statements**

The Company has followed the Indian Accounting Standards notified under Section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards (Ind AS)) Rules, 2015 in preparation of its financial statements.

- **Code of Conduct**

The company has adopted a code of conduct for the members of the Board and for every employee of the Company in compliance with the provisions of Listing Regulations. Commitment to ethical professional conduct is a must for every employee, including Board members and senior management. The code is intended to serve as a basis of ethical decision making in conduct of professional work. The code of conduct enjoins that each individual in the must know and respect existing laws, accept and provide appropriate professional views, and be upright in his conduct and observe corporate discipline All Board members and senior Management personnel affirm compliance with the code of conduct annually. The Code of conduct has been posted on the website of the company at <https://ajoonibiotech.com/> and direct link to the code of conduct is at https://ajoonibiotech.com/Uploads/Policy/Code%20of%20Conduct_.pdf.

A declaration signed by the Managing Director (MD) to this effect is given below:

“I hereby confirm that, the Company has obtained affirmation from all the members of the Board and Senior Management, that they have complied with the Code of Conduct for Directors and Senior Management in respect of the financial year 2020-21.”

Place: Mohali
Date :27.08.2021

Jasjot Singh
Managing Director

- **Pledge of Equity Shares**

No pledge has been created over the equity shares held by either Promoters and/or Promoter Group Shareholders as on March 31, 2021.

- **Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)**

During the year under review, company issued 6,00,000 equity shares at Rs. 20 each (including premium of Rs. 15/-) on preferential basis. Further, company issued additional 10,00,558 bonus shares in the ratio of 1:9.

- **Details of Directors appointed/Reappointed**

Details of Directors being appointed / re-appointed, have been disclosed in the Notice and Explanatory statement attached thereto for the AGM, i.e. a brief resume, nature of expertise in specific functional areas, names of directorships and committee memberships and their shareholding in the Company.

- **Management**

The management discussion and analysis report giving an overview of the Industry, Company's Business and its financials is provided separately as a part of this Annual Report.

- **Insider trading**

Pursuant to Securities and Exchange Board of India [Prohibition of Insider Trading] Regulations the company has prescribed a Code of Conduct for Prevention of Insider Trading and a Code of Corporate Disclosure Practices.

The code lays down guidelines and procedures to be followed and disclosures to be made while dealing with securities of the company. Under this code, Directors including Insiders (i.e. Designated Employees) are prevented from dealing in the Company's shares. To deal in Securities beyond specified limits, permission of Compliance Officer is required. All Designated Employees are also required to disclose related information as defined in the Code. The purpose of the code is also to guide company's transaction and dissemination of price sensitive information to outside agencies and to ensure timely and adequate disclosures thereof to regulatory authorities on a continuous basis.

- **Subsidiary companies**

The Company does not have any subsidiary company.

- **A certificate from a company secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority.**

The Company has obtained a Certificate pursuant to the Regulation 34(3) read with Schedule V of the Listing Regulations, from a Practising Company Secretary, confirming that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Directors of companies either by Securities and Exchange Board of India or the Ministry of Corporate Affairs or any other Statutory Authorities. The said certificate forms part of this report.

- **Where the board had not accepted any recommendation of any committee of the board which is mandatorily required, in the relevant financial year:**

Not Applicable

- **Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part.**

Details of remuneration paid to Auditors of the Company are provided below:

Sr. No.	Particulars	Amount (In Rs.)
1	Audit Fees	70,800
Total		70,800

- **Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:**

The details relating to the same are provided in the Board's report.

(11) THE CORPORATE GOVERNANCE REPORT SHALL ALSO DISCLOSE THE EXTENT TO WHICH THE DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II HAVE BEEN ADOPTED

The Company fulfills the following discretionary requirements pursuant to Regulation 27(1) of the SEBI Listing Regulations read with Part E of Schedule II.

(12) CEO/CFO CERTIFICATION

As required under Regulation 17(8) of the SEBI Listing Regulations, the Chairman and Managing Director and the Chief Financial Officer of the Company have certified to the Board, the Financial Statements for the year ended March 31, 2021 and the certificate is annexed to this report.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021
Place: Mohali

Jasjot Singh
Managing Director
DIN: 01937631

Gursimran Singh
Director
DIN: 02209675

ANNEXURE 'E' TO DIRECTORS' REPORT

MANAGEMENT DISCUSSION AND ANALYSIS REPORT**A. CAUTIONARY STATEMENT:**

The statements in the "Management Discussion and Analysis Report" describe the Company's objectives, projections, expectations, estimates or forecasts which may be "forward-looking statements" within the meaning of the applicable laws and regulations. Actual results may differ substantially or materially from those expressed or implied therein due to risks and uncertainties. Important factors that could influence the Company's operations, inter alia, include global and domestic demand and supply conditions affecting selling prices of finished goods, input availability and prices, changes in government regulations, tax laws, economic, political developments within the country and other factors such as litigations and industrial relations.

B. COVID-19 UPDATE

The unprecedented COVID-19 outbreak has significantly impacted economies across the globe and India is no exception. With the strict lockdown imposed at the beginning of the Financial Year 2020-21, demand and supply were disrupted in India. However, the impact of the lockdown and economic disruption was different in different sectors. Agriculture and allied services, the sector in which your Company operates, was classified under essential goods and services and operations were allowed during the lockdown. Therefore, the manufacturing plant of your Company were functional with in a week's time after obtaining the necessary approvals from the relevant Government authorities.

The Company efficiently conducted business through virtual meetings with multiple stakeholders including distributors, vendors, dealers and farmers.

C. INDIAN ECONOMY AND AGRICULTURE OVERVIEW:

Considering the sector-wise growth, while the output for all the sectors declined over the previous year but agriculture sector has seen growth of 3.6%. however demand was lower across sectors due to lockdown and the supply of goods and services was disrupted mainly due to the non-availability of labour and logistics constraints. Agricultural activities and allied businesses like Dairy or Fisheries on which our business of cattle feed is dependent were categorized under essential goods and services and this coupled with favourable macro indicators and timely Government support resulted in the agriculture sector performing better than others.

D. KEY BUSINESS SEGMENTS:

The company deals in a Single segment.

E. COMPANY'S FINANCIAL AND OPERATIONAL PERFORMANCE:

For the Financial Year 2020-21, your Company reported total income of Rs. 51.04 Crores as compared to 40.03 Crores in the previous Financial Year. Profit before tax stood at Rs. 50.42 lacs as compared to 48.07 Lacs reported in the previous Financial Year.

F. OPPORTUNITIES, STRENGTHS, THREATS, RISKS & CONCERNS:**(i) Opportunities and Strengths:**

- *Scope of Increase market share:*

The Company's ability to increase sales will be strengthened by continued focus on offering a wide range of innovative products which will help in gaining market share. Also in the medium-term, due to strict government laws to be implemented very shortly leading to the closure of unorganised sector units, corporate and larger players will gain market share.

• ***Strong Research & Development (R&D) Capabilities:***

The Company's emphasis on R&D has been critical to its success and a differentiating factor from competitors. Dedicated R&D is undertaken in existing products primarily with a focus to improve yields and process efficiencies. Investment is also being made in developing innovative technologies to further growth of the product portfolio

(ii) Threats, Risks & Concerns:

• ***Adverse economic impact of COVID-19 pandemic:***

If the COVID-19 pandemic continues for a very long time leading to lockdowns, it can disrupt economic activity. It can lead to issues regarding unavailability of labour, inter-state trade movements etc. which can adversely impact the businesses of the company.

• ***Availability of raw materials and arrangements with suppliers for raw materials:***

The price and availability of raw materials which is basically agriculture residues depend on several factors beyond the Company's control, including overall economic conditions, production levels, market demand and competition for such materials, production and transportation cost, duties and taxes and trade restrictions. The Company typically sources raw materials from third-party suppliers or the open market which exposes the Company to volatility in the prices of raw materials and dependence on third-party for delivery of raw material may adversely affect operations.

• ***Seasonal variations in the businesses:***

Your Company's businesses are subject to seasonal variations that could result in fluctuations in performance. The Company sells lower volumes of cattle feed during the monsoons due to the availability of green fodder. As a result of such seasonal fluctuations, sales and results of operations may vary by fiscal quarter, and the sales and results of operations of any given fiscal quarter may not be relied upon as indicators of the sales or results of operations of other fiscal quarters or future performance. In addition, financial performance is also impacted by other risks such as inability to manage diversified operations, dependency of revenue from animal feed business and dependency of the utilization of services of third parties for our operations.

G. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

Your Company remains committed to improve the effectiveness of internal control systems for business processes with regard to its operations, financial reporting and compliance with applicable laws and regulations. The Company has a proper system of internal controls to ensure that all assets are safeguarded and protected against loss from unauthorized use or disposition and that all transactions are authorized, recorded and reported correctly.

H. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES:

The workforce is a critical factor in maintaining quality and safety, which strengthens the competitive position and the human resource policies focus on training and retaining of the employees of the Company. The Company trains employees regularly to increase the level of operational excellence, improve productivity and maintain compliance standards on quality and safety. Employees are offered performance-linked incentives and benefits and the Company conducts employee engagement programs from time to time. The Company also hires contract labour from time to time. The management team comprises of professionals with a proven track record. The

Company continues to remain focused and sensitive to the role of human resources in optimizing results in all its areas of working and its industrial relations also continue to be cordial.

By Order of the Board of Directors
For Ajooni Biotech Limited

Date: 27.08.2021
Place: Mohali

Jasjot Singh
Managing Director
DIN: 01937631

Gursimran Singh
Director
DIN: 02209675

ANNEXURE 'F' TO DIRECTORS' REPORT

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO PURSUANT TO THE PROVISIONS OF SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH THE COMPANIES (ACCOUNTS) RULES, 2014:

A. CONSERVATION OF ENERGY:

- **Steps taken for conservation:** The Company continues to give high priority to conservation of energy on an on-going basis by preventive maintenance of electric equipments and ensured optimum utilization of electric energy.
- **Steps taken for utilizing alternate sources of energy:** -
- **Capital investment on energy conservation equipments:-** It can be planned through replacement of and modification of inefficient equipments and by providing automatic controls to reduce idle running of equipments

B. TECHNOLOGY ABSORPTION:

- **Efforts made for technology absorption:** Keeping constant touch with the new technologies.
- **Benefits derived:** to achieve the best level of quality achievement.
- **Expenditure on R&D:**
- **Technology imported:** The Company has not imported any technology.
- **Year of Import:** N.A.
- **Has technology been fully absorbed:** NA
- **Areas where this has not taken place:** N.A.

C. FOREIGN EXCHANGE EARNINGS AND OUTGO (2020-21)

Foreign Exchange earnings :- Nil
Foreign Exchange outgo :- NIL

ANNEXURE 'G' TO DIRECTORS' REPORT

Form No. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2021

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members
AJOONI BIOTECH LIMITED
CIN: L85190PB2010PLC040162
D-118, INDUSTRIAL AREA, PHASE-7,
MOHALI, PUNJAB-160059.

Dear Sir(s)

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s. AJOONI BIOTECH LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the **M/s. AJOONI BIOTECH LIMITED** books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period ended on **31/03/2021**, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

We have examined the books, papers, minute books, forms and returns filed and other records maintained by **M/s. AJOONI BIOTECH LIMITED** ("the Company") for the financial year ended on **31/03/2021** according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the Rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **Not Applicable as company has not accepted/made any FDI, ODI or ECBs during the Financial Year under review.**
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') to the extent applicable to the Company:
 - a. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
 - b. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - c. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - d. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - e. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not Applicable as the Company did not issue any ESOP or ESPs during the Financial Year under review.**
 - f. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **Not Applicable as the Company did not issue any debt securities during the Financial Year under review.**

- g. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share transfer Agent during the year under review.**
- h. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **Not Applicable as the Company has not delisted its Equity shares from any Stock Exchange during the financial year under review** and
- i. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back any of its securities during the Financial Year under review.**
- VI. Based on the representation made by the Company and its officers, the Company has proper system and process in place for compliance under the other applicable Laws, Acts, Laws, Rules, Regulations, Guidelines and Standards as applicable to the Company are given below:
- i) The Environment (Protection) Act 1986
 - ii) Air (Prevention and Control of Pollution) Act, 1981
 - iii) The Water (Prevention and Control of Pollution) Act, 1974
 - iv) GST (Goods & Service Tax) Laws, Excise Laws, Sales Tax Laws
 - v) Income Tax Act, 1961.
 - vi) Food Safety and Standards Act, 2006
 - vii) Labour Laws related to labour and employees appointed by the Company either on its payroll or on contractual basis as related to wages, gratuity, provident fund, Employee State Insurance etc.
 - viii) MSMED Act, 2006
 - ix) Trademark Act, 1999
 - x) Legal Metrology Act, 2009
 - xi) The Electricity Act, 2003 and the Electricity Rules 2005
 - xii) The Factories Act, 1948
 - xiii) The Payment of Bonus Act, 1965
 - xiv) The Employees Provident Fund and Miscellaneous Provisions Act, 1952

We have also examined compliance with the applicable clauses of the following:

- i) The Institute of Company Secretaries of India has prescribed Secretarial Standards which are mandatory for the year 2020-2021.
- ii) The provisions of the Listing Agreements entered into by the Company with the Stock Exchanges.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, Listing Agreements etc mentioned above **subject to the following observations/note:**

1. *During the year under review National Stock Exchange of India Limited had imposed a penalty of Rs. 11,800/- on the company for Non-compliance of Regulation 29(2)/(3) of SEBI (LODR) Regulations, 2015 and Rs. 47,200/- for Non- Compliance of SEBI (ICDR) Regulations, 2018.*
2. *The company did not publish the Notice of Annual General Meeting held on 10th September, 2020.*

We further report that:

The Board of Directors of the Company is constituted with proper mix of Executive Directors, Non-Executive Directors and Independent Directors. Further, changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice was given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decisions were carried through while the dissenting members' views were captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, in pursuance of the above referred laws, rules, regulations, guidelines etc. having a major bearing on the material affairs, the company has:

- (i) Increased its authorised capital to Rs. 16,00,00,000/- divided into 1,60,00,000 equity shares of Rs. 10/- each.
- (ii) Issued and allotted 6,00,000 equity shares at a price of Rs. 20/- each (including Rs. 10/- as premium) on preferential basis to its Promoter(s).
- (iii) Issued and allotted 10,00,558 equity shares through Bonus Issue on 13th March, 2021.

**FOR M.R. CHECHI & ASSOCIATES
COMPANY SECRETARIES**

UDIN: F003823C000701841.

Place: Chandigarh

Dated: 28th July, 2021.

**MAST RAM CHECHI
M. NO.: 3823; CP NO.: 2906**

Annexure-A

TO,
THE MEMBERS,
AJOONI BIOTECH LIMITED.
CIN: L85190PB2010PLC040162.
D-118, INDUSTRIAL AREA, PHASE-7,
MOHALI, PUNJAB-160059.

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records.

The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness and the Compliance by the Company abiding and adherence to applicable financial and taxation laws like direct taxation and indirect taxation laws and maintenance of financial records and books of accounts has not been reviewed in this Audit since the same have been subject to review by Statutory Financial Auditor and other designated professionals

4. Wherever required, we have obtained the Management's representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. Our examination was limited to the verification of the procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**FOR M.R. CHECHI & ASSOCIATES
COMPANY SECRETARIES**

UDIN: F003823C000701841.

Place: Chandigarh

Dated: 28th July, 2021

**MAST RAM CHECHI
M. NO.: 3823; CP NO.: 2906**

DISCLOSURES TO ANNUAL REPORT

(Pursuant to regulation 34(3) & 53(f) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015)

A) RELATED PARTY DISCLOSURE

S.NO.	IN THE ACCOUNTS OF HOLDING/ SUBSIDIARY COMPANY	DISCLOSURES OF AMOUNTS AT THE YEAR END AND THE MAXIMUM AMOUNT OF LOANS/ ADVANCES/ INVESTMENTS OUTSTANDING DURING THE YEAR.
The Company Does Not Have Any Holding or Subsidiary Company, hence no amount of loans, advances or investments is outstanding during the year.		

B) DECLARATION

I, Gursimran Singh, CEO of the Company hereby state that the members of the board of directors and senior management personnel have affirmed compliance with the code of conduct of board of directors and senior management on an annual basis.

**On behalf of the Board
For Ajooni Biotech Limited
Sd/-
Gursimran Singh (CEO)**

C) COMPLIANCE CERTIFICATE [As per Regulation 17(8) of SEBI (LODR) Regulation, 2015]

To,
The Board of Directors,
Ajooni Biotech Limited

We Jasjot Singh, Chairman & Managing Director and Gurmeet Singh, Chief Financial Officer of the Company hereby certify that in respect of the financial year ended on March 31, 2021:

We have reviewed financial statements and the cash flow statement for the year March 31, 2021 and that to the best of their knowledge and belief:

1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
2. These statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
3. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.

We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

We have indicated to the auditors and the Audit committee:

1. significant changes in internal control over financial reporting during the year;
2. significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
3. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

Place: Mohali
Date: 23/06/2021

Sd/-
Jasjot Singh
Managing Director

Sd/-
Gurmeet Singh
CFO

D) AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members
Ajooni Biotech Limited,

We have examined the compliance of conditions of Corporate Governance by Ajooni Biotech Limited for the year ended on 31st March 2021 as stipulated in the listing regulations of the SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015. Since, during the year under review, company being listed on the SME Platform of the National Stock Exchange, the company was not required to submit submit the Corporate Governance Report as per the applicability regulation 15 (2) of the SEBI (Listing Obligation & Disclosure Requirement) Regulations, 2015.

Management's Responsibility

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination has been limited to a review of the procedures and implementation thereof adopted by the company for ensuring compliance with the conditions of Corporate Governance as stipulated in the said clause. It is neither an audit nor an expression of opinion on the financial statement of the company.

Opinion

On the basis of our review of the relevant records and documents maintained by the company and furnished to us for internal review and the information and explanation given to us by the company we certify that the company complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations, 2015

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency with which the Management has conducted the affairs of the Company.

Restriction on use

This certificate is issued solely for the purpose of complying with the aforesaid regulations and may not be suitable for any other purpose.

For Harjeet Parvesh & Co.
CHARTERED ACCCOUNTANTS (FRN: 017437N)
CA Konica Madan (Partner)
PLACE: Mohali
DATE: 11/08/2021

ANNEXURE 'H' TO DIRECTORS' REPORT

Independent Auditor's Report

To
The Members of M/s Ajooni Biotech Limited

Opinion

We have audited the accompanying standalone financial statements of M/s Ajooni Biotech Limited which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (statement of changes in equity), Cash Flow Statement for the year then ended, notes to the financial statements and a summary of significant accounting policies and other explanatory information. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid (Standalone) financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and its Profit, (changes in equity) for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease

operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the audit of the Standalone Financial Statements

Our responsibility is to express an opinion on these (Standalone) financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure-A**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account
 - d) In our opinion, the aforesaid (Standalone) financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Harjeet Parvesh & Co.
Chartered Accountants
FRN: 017437N
CA Konica Madan
Partner
M.No 547759

UDIN: 21547759AAAAAR8186
Place: MOHALI
Date: 23/06/2021

Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2021:

1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;

(b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.

(c) The title deeds of immovable properties are held in the name of the company.

2) (a) The Management has conducted Physical verification of inventory at reasonable intervals.

(b) There were No Discrepancies noticed on physical verification of the inventory.

3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (C) of the Order are not applicable to the Company and hence not commented upon.

4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.

5) The Company has not accepted deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.

7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, Duty of Excise, Goods and Service Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2021 for a period of more than six months from the date on when they become payable.

b) According to the information and explanation given to us, there are no dues of income tax, GST, duty of customs, duty of excise, value added tax outstanding on account of any dispute.

8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.

9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised any moneys by way of initial public offer or further public offer including debt instruments and term loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.

- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of the Order are not applicable to the Company.
- 13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14) Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment of shares or private placement of shares or fully or partly convertible debentures during the year under review. . Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.
- 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause (xv) of the Order are not applicable to the Company and hence not commented upon.
- 16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause (xvi) of the Order are not applicable to the Company and hence not commented upon.

For Harjeet Parvesh & Co.
Chartered Accountants
FRN: 017437N
CA Konica Madan
Partner
M.No 547759

UDIN: 21547759AAAAAR8186
Place: MOHALI
Date: 23/06/2021

Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of M/s Ajooni Biotech Limited
Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of M/s **Ajooni Biotech Limited** (“the Company”) as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by

ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021.

UDIN: 21547759AAAAAR8186

Place: MOHALI

Date: 23/06/2021

For Harjeet Parvesh & Co.

Chartered Accountants

FRN: 017437N

CA Konica Madan

Partner

M.No 547759

AJOONI BIOTECH LIMITED			
BALANCE SHEET AS AT 31ST MARCH 2021			
PARTICULARS	NOTES	31.03.2021	31.03.2020
I) ASSETS			
(1) Non-current assets			
a) Property , Plant & Equipment	1	5,16,17,081.00	2,07,15,278.00
b) Financial Assets			
1. Non-Current Investment	2	1,14,82,856.00	3,07,86,506.00
2. Advances			
c) Deferred Tax Assets		14,65,029.00	12,73,605.00
d) Other Non Current Assets	3	14,07,030.00	28,14,060.00
(2) Current assets			
a) Inventories	4	5,37,62,090.00	3,28,56,814.00
b) Financial Assets			
1) Cash & Cash Equivalent	5	24,40,976.00	12,38,879.00
2) Short Term Loans and advances	6	1,98,82,931.00	1,24,66,892.00
3) Trade Receivables	7	13,71,17,389.00	12,64,18,512.00
(c) Other Current Asset	8	10,87,547.00	21,04,378.00
TOTAL		28,02,62,930.00	23,06,74,924.00
II) EQUITY AND LIABILITIES			
(1) Equity			
a) Equity Share Capital	9	10,00,55,820.00	8,40,50,240.00
b) Other Equity	10	5,64,51,410.00	7,48,59,992.00
(2)Non - Current Liabilities			
a) Financial Liabilities			
(1)Borrowing	11	1,89,79,313.00	1,33,07,393.00
(3)Current Liabilities			
a) Financial Liabilities			
1) Borrowings	12	4,88,57,260.00	3,69,45,933.00
2) Trade Payables	13	5,40,03,957.00	1,93,28,252.00
b) Other Current Liabilities	14	4,11,890.00	4,99,582.00
c) Current Tax Liabilites (Net)	15	15,03,280.00	16,83,532.00
TOTAL		28,02,62,930.00	23,06,74,924.00

Notes on Accounts

Notes '1' to '15' and Note '25'

Form Integral part of the Balance Sheet

For and on behalf of the Board

As per our separate report of even date attached

Jasjot Singh
(Managing Director)

Gursimran Singh
(Director)

For Harjeet Parvesh & Co.
Chartered Accountants

Gurmeet Singh
CFO
Date: 23/06/2021
Place: Mohali

Swati Vijan
CS

CA Konica Madan
M.No 547759

AJOONI BIOTECH LIMITED			
STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2021			
PARTICULARS	NOTES	31.03.2021	31.03.2020
Revenue from operation	16	51,03,88,901.00	40,03,26,163.00
Other Income	17	1,72,109.00	5,98,511.00
Total Revenue		51,05,61,010.00	40,09,24,674.00
EXPENSES			
Cost of Material Consumed	18	43,35,59,989.00	34,93,59,567.00
Change in Inventories of FG/ WIP/Stock in Trade	19	-34,32,815.00	-2,39,538.00
Employee benefit Expenses	20	1,14,78,437.00	1,11,80,858.00
Financial Cost	21	58,40,690.00	32,79,206.00
Depreciation Expenses	22	57,75,160.00	49,19,813.00
Other Expenses			
Operating Expenses	23	1,20,36,277.00	70,91,944.00
Administrative Expenses	24	4,02,60,898.00	2,05,25,733.00
Total Expenses		50,55,18,636.00	39,61,17,584.00
Net Profit before Income Tax & Exceptional Items		50,42,374.00	48,07,089.00
Profit before Tax			
TAX EXPENSES :			
1. Current Tax		15,03,280.00	16,83,532.00
2. Deferred Tax	25	1,91,424.00	3,44,455.00
Profit for the Period		37,30,518.00	34,68,012.00
OTHER COMPREHENSIVE INCOME			
<i>Items that will not be classified to Profit & Loss</i>			
Changes in Fair Value of FVOCI Equity Instruments	2	-1,61,29,155.00	-
Loss on Sale of shares		-20,04,365.00	-
OTHER COMPREHENSIVE INCOME FOR THE YEAR		-1,81,33,520.00	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		-1,44,03,002.00	34,68,012.00
Earning per Equity Share :	25		
(1) Basic		0.37	0.41
(2) Diluted		0.37	0.41

Notes on Accounts

Notes '16' to '24' and Note '25'

Form Integral part of the Accounts

As per our separate report of even date attached

For and on behalf of the Board

For Harjeet Parvesh & Co.
Chartered Accountants

Jasjot Singh	Gursimran Singh	Gurmeet Singh	Swati Vijan
(Mg. Director)	(Director)	(CFO)	(CS)

CA Konica Madan
M.No 547759

Date: 23/ 06/2021

Place: Mohali

AJOONI BIOTECH LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2021

		CURRENT YEAR 2021	PREVIOUS YEAR 2020	
"A" (1)	CASH FLOW FROM OPERATING ACTIVITIES			
	Profit/(Loss) Before Tax	50,42,373.67	48,07,089.69	
	Adjustments for:			
	Depreciation & Amortization	43,68,129.61	35,12,793.49	
	(Profit)/loss on sale of Assets/shares	-	3,22,016.17	
	Interest & Finance Charges	58,40,690.00	32,79,206.24	
	Interest Income	-2,137.00	-7,19,948.00	
	Dividend Income	-	1,02,06,682.56	
		-7,500.00	63,86,567.90	
	Operating Profit before Working Capital Changes	1,52,49,056.23	1,11,93,657.59	
	Adjustments for:			
	Decrease/(Increase) in Receivables	-1,06,98,877.47	7,80,85,113.05	
	Decrease/(Increase) in Inventories	-2,09,05,276.74	1,78,32,116.05	
	Decrease/(Increase) in Loans and Other Advances	-74,16,039.07	-26,33,693.65	
	Decrease/(Increase) in Other Current Assets	10,16,831.00	48,446.00	
	Increase/(Decrease) in Trade Payables	3,46,75,705.66	76,85,673.72	
	Increase/(Decrease) in Other Current Liabilities (including Provisions)	-2,68,779.20	-35,96,435.82	
		1,54,252.00	-5,49,98,318.93	
	Cash generated from operations	11,65,26,204.41	4,38,04,661.34	
	Tax paid/refund	95,414.65	42,970.00	
	Net Cash flow from Operating activities	11,57,20,576.76	-4,38,47,631.34	
(2)	CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Tangible Assets/ Intangible Assets/ Capital Work-In-Progress	-3,52,69,932.00	-1,40,08,417.00	
	(Increase)/Decrease by sale/purchase in Non-Current Investments	11,70,130.00	1,80,25,570.28	
	(Increase)/ Decrease in Fixed Deposits	-		
	Interest Income	2,137.00	7,19,948.00	
	Dividend Income		7,500	
	Net Cash used in Investing	-3,40,97,665.00	47,44,601.28	

activities				
(3)	CASH FLOW FROM FINANCING ACTIVITIES			
	Share premium	60,00,000.00		1,12,50,000.00
	Proceeds from Issue of Share Capital	60,00,000.00		2,25,00,000.00
	Proceeds from/ (Repayment) of Long term Borrowings	56,71,920.00		-2,82,65,668.20
	Increase/(Decrease) in Short Term Borrowings	1,19,11,326.68		3,08,29,303.98
	Interest and Other Finance Costs paid	-58,40,689.95		-32,79,206.24
	Net Cash used in Financing activities		2,37,42,556.73	33034429.54
"B"	Net increase in cash & Cash Equivalents		12,02,097.49	-60,68,600.52
	Add: Cash and Cash equivalents at the Beginning of the Year		12,38,879.18	73,07,480.06
"C"	Cash and Cash equivalents at the End of the Year		24,40,976.31	12,38,879.18
	Cash & Cash Equivalents at the end of the year		CURRENT YEAR 2021	PREVIOUS YEAR 2020
	Cash in Hand		23,08,213.97	9,12,787.00
	Cash at Bank		1,32,762.34	3,26,092.18
	Cash & Cash equivalents as stated		24,40,976.31	12,38,879.18

FOR AND ON BEHALF OF THE BOARD

Jasjot Singh
Managing Director

Gursimran Singh
Director

Gurmeet Singh
CFO

Swati Vijan
CS

Date: 23.06.2021
Place: Mohali

AUDITOR'S REPORT

As per our report of even date
For HARJEET PARVESH & Co
CHARTERED ACCOUNTANTS

CA Konica madan
M.No. 547759

NOTES FORMING PART OF BALANCE SHEET AND STATEMENT OF PROFIT AND LOSS

PARTICULARS	31ST MARCH 2021	31ST MARCH 2020
Note No. 2 Non Current Investments		
Quoted Shares (valued at Fair Value in Current Year)	1,14,82,856	3,07,86,506
Total Rs.	1,14,82,856	3,07,86,506
Particulars	31ST MARCH 2021	31ST MARCH 2020
	Amount (Rs.)	Amount (Rs.)
EQUITY investments at FVOCI		
Quoted Shares of:		
- M/s Prism Medico And Pharmacy Ltd '(M.v as on 31.03.2021 of 927397 Eq.Shares @ Rs.11.65/- 'i.e. Rs. 10804175.05/-)	1,08,04,175.05	2,59,67,116.00
- M/s Hi-Tech Pipes Limited		31,74,495.00
- M/s New Light Apparels Limited (M.v as on 31.03.2021 of 5000 Eq.Shares@ Rs.27/- i.e. Rs. 135000/-)	1,35,000	1,40,390.00
- M/s Rama Steel Tubes Limited (M.v as on 31.03.2021 of 5815 Eq.Shares@ Rs69.95 /- i.e. Rs. 406759.25/-)	4,06,759.25	11,10,543.53
- M/s Kuber Udyog Ltd (M.v as on 31.03.2021 of 3200 Eq.Shares@ Rs.0.71/- i.e. Rs.2272)	2,272.00	12,910.00
- M/s Rajoo Engineers (M.v as on 31.03.2021 of 6835 Eq.Shares@ Rs.19.7/- i.e. Rs. 134649.5)	1,34,649.50	3,81,051.34
Total Rs.	1,14,82,855.80	3,07,86,505.87

Note No. 3 Other Non Current Assets	31ST MARCH 2021	31ST MARCH 2020
IPO Expenses unamortized	14,07,030	28,14,060
Total Rs.	14,07,030	28,14,060

Note No. 4 Inventories (As per inventories taken, valued and certified by the management)	31ST MARCH 2021	31ST MARCH 2020
Raw material(incl. Packing material)	4,86,09,854	3,11,37,393
Finished goods/ Traded Goods	51,52,236	17,19,422
Total Rs.	5,37,62,090	3,28,56,815

Note No. 5 Cash & Cash Equivalents	31ST MARCH 2021	31ST MARCH 2020
Cash In Hand	23,08,214	9,12,787
Cash at Bank	1,32,762	3,26,092
Total Rs.	24,40,976	12,38,879

Note No. 6 Short Term Loans & Advances	31ST MARCH 2021	31ST MARCH 2020
Advance Tax	10,00,000	-
Tax Collected at Source	93,639	-
Input Tax Credit-GST	12,560	3,14,345
Prepaid Insurance	1,48,759	1,46,591
Advances to Suppliers	78,83,689	74,48,040
Staff Advances	4,32,766	2,66,356
Other Advances	87,09,970	36,30,560
Securities	16,01,548	6,61,000
Total Rs.	1,98,82,931	1,24,66,892

Note No. 7 Trade Receivables	31ST MARCH 2021	31ST MARCH 2020
Sundry Debtors	13,71,17,389	12,64,18,512
Total Rs.	13,71,17,389	12,64,18,512

Note No. 8 Other Current Assets	31ST MARCH 2021	31ST MARCH 2020
Recoverables from Govt. Authorities '- Value Added Taxes	10,87,547	21,04,377
Total Rs.	10,87,547	21,04,377

Note No. 9 Equity Share Capital	31ST MARCH 2021	31ST MARCH 2020
Authorised		
1600000 Equity Shares of Rs 10/- Each	16,00,00,000	10,00,00,000
Increase in Authorised Share Capital consists of 600000 Equity Shares of Rs 10/- each		
ISSUED, SUBSCRIBED AND PAID UP		
8405024 Equity Shares of Rs. 10/- each (Fully Paid-up)	8,40,50,240	8,40,50,240
Add: Bonus Issue of Shares	10,00,55,820	
Add: Shares allotted during the year	60,00,000	
Total Rs.	10,00,55,820	8,40,50,240

Note:

- 600000 Equity shares Rs 10/- each allotted to Mr. Jasjot Singh on 10.11.20 at premium of Rs 10 each

2. 1000558 Equity shares issued as bonus shares in proportion of 1 share for every 9 shares held by existing members.

(c) Statement of Changes in Equity

PARTICULARS	As at 31st March,2021		As at 31st March,2020	
	No of Shares	Amount	No of Shares	Amount
Equity Shares at the beginning of the year	84,05,024.00	8,40,50,240.00	61,55,024.00	6,15,50,240.00
Add: Equity Shares allotted during the year	16,00,558.00	1,60,05,580.00	22,50,000	2,25,00,000.00
Equity Shares at the end of the year	1,00,05,582.00	10,00,55,820.00	84,05,024.00	8,40,50,240.00

Shareholders holding more than 5 % shares	No. of Equity shares	% of Holding
Healthy Biosciences Pvt Ltd	13,82,296	13.82%
Prism Medico & Pharmacy Ltd	6,46,476	6.46%
Ms.Upneet Kaur	7,74,718	7.74%
Mrs.Ishneet Kaur	6,76,418	6.76%
Mr Jasjot Singh	16,86,720	16.86%

Note No. 10 Other Equity		31 ST MARCH 2021	31 ST MARCH 2020	
Total Rs.		5,64,51,410	7,48,59,992	
PARTICULARS	general reserve & retained earnings (in Rs)	securities premium reserve (in Rs)	Items of OCI(In Rs)	Total Other Equity
Balance on 1.04.2019	4,72,72,984	1,28,22,782		6,00,95,766
Profit for the year	34,86,012.125			34,68,012
Share Premium		1,12,50,000		1,12,50,000
Add / Less : Income Tax Adjustment	46,214			46,214
Balance on 31.03.2020	5,07,87,210	2,40,72,782		7,48,59,992
Balance on 1.04.2020	5,07,87,210	2,40,72,782		7,48,59,992
Pofit for the year	37,30,518			37,30,518
shares premium		6,00,000		6,00,000
Bonus issue of shares	-1,00,05,580			-1,00,05,580
Items of Other Comprehensive			-1,81,33,520	-1,81,33,520

Income				
Balance on 31.03.21	4,45,12,148	3,00,72,782	-1,81,33,520	5,64,51,410

Note No. 11 Long Term Borrowings	31ST MARCH 2021	31ST MARCH 2020
Secured Borrowings (Annexure A)	1,81,79,313	15,37,953
Unsecured Borrowings	8,00,000	1,17,69,440
Total Rs.	1,89,79,313	1,33,07,393

Note No. 12 Short Term Borrowings	31ST MARCH 2021	31ST MARCH 2020
Current Maturities of Long Term Debt (annexure A)	92,35,038	7,86,250
Canara Bank CC Limit	3,96,22,221.68	3,61,59,683
--CC limit enhanced by bank on 18.09.2020 from existing limit of 395 lacs to 495 Lacs		
Total Rs.	4,88,57,260	3,69,45,933

Primary Security:

Stock under Raw Material, Work Finished goods & Receivables

Collateral Security:

EMT of Land & Building at D-118, Industrial Area Phase-7 Mohali, Market Value 602 lacs

Additional EMT OF Land & Building Situated at D 12 Focal Point ,in name of KHANNA SOLVEX through its partners Sh Jasjot Singh & Smt Paramjeet Singh, MV 200.07 LACS

Personal Gurantee of Sh Jsot singh, Sh Partek Singh & Sh Gurmeet Singh

Corporate Gurantee of M/s Healthy Biosciences & M/S Khanna Solvex

Note No. 13 Trade Payables	31ST MARCH 2021	31ST MARCH 2020
Sundry Creditors		
-Raw materials	4,83,83,601	1,53,82,442
-Others	44,59,820	19,53,954
Expenses Payable	11,60,537	19,91,856
Total Rs.	5,40,03,957	1,93,28,252

Note No. 14 Other Current Liabilities	31ST MARCH 2021	31ST MARCH 2020
Other payables		
-Statutory Remittance	3,15,165	1,93,112
Advances from Customers/Others	30,425	2,52,470
Audit Fees Payable	66,300	54,000
Total Rs.	4,11,890	4,99,582

Note No. 15 Current Tax Liability	31ST MARCH 2021	31ST MARCH 2020
Tax payable for the year	15,03,280	16,83,532
Total Rs.	15,03,280	16,83,532

Note No. 16 Revenue from Operations	31ST MARCH 2021	31ST MARCH 2020
(i) Sale of Products:		
'- Domestic Sales	51,03,88,901	40,03,26,163
Total Rs.	51,03,88,901	40,03,26,163

Note No. 17 Other Income	31ST MARCH 2021	31ST MARCH 2020
(i) Income from Share Dividend	-	7,500
(ii) Rebate & Discount	1,65,964	1,82,574
(iii) Interest	2,137	7,19,948
(iv) Round off	3,108	10,505
(v) Misc Income	900	-
(vi) Profit/Loss on Shares	-	-3,22,016
Total Rs.	1,72,109	5,98,511

Note No. 18 Cost of Material Consumed	31ST MARCH 2021	31ST MARCH 2020
Opening Stock of Raw material & Packing Material	3,11,37,393	4,92,09,047
Add: Purchases of Raw material & Packing Material	44,73,31,774	32,85,86,585
Add: Direct expenses	37,00,676	27,01,328
Less: Closing Stock of Raw material & Packing Material	4,86,09,854	3,11,37,393
Total Rs.	43,35,59,989	34,93,59,567

Note No. 19 Change in Inventories	31ST MARCH 2021	31ST MARCH 2020
- Finished Goods / Traded Goods		
Closing Stock of Finished goods	22,41,359	5,92,478
Closing Stock of Traded Goods	29,10,877	11,26,944
Less Opening Stock of Finished Goods	5,92,478	7,36,644
Less Opening Stock of Traded Goods	11,26,944	7,43,240
Total Rs.	-34,32,815	-2,39,538

Note No. 20 Employee Benefit Expenses	31ST MARCH 2021	31ST MARCH 2020
(i) Salary, Wages & Allowances	98,67,503	1,02,38,509
(ii) Staff Welfare Expenses	10,17,473	4,05,391
(iii) Medical Expenses	4,887	88,635

(iv) Bonus	1,61,584	44,600
(v) PF Expenses	2,72,467	2,50,823
(vi) ESI Expenses	1,54,523	1,52,900
(vii) Labour Welfare	-	-
Total Rs.	1,14,78,437	1,11,80,858

Note No. 21 Finance Cost	31ST MARCH 2021	31ST MARCH 2020
Bank Charges & Interest	49,40,079	31,48,521
Processing Fees	90,0611	1,30,685
Total Rs.	58,40,690	32,79,206

Note No. 22 Depreciation Expense	31ST MARCH 2021	31ST MARCH 2020
Depreciation on Fixed Assets	43,68,130	35,12,793
Preliminary Expenses W/o	14,07,030	14,07,020
Total Rs.	57,75,160	49,19,813

Note No. 23 Other Operating Expenses	31ST MARCH 2021	31ST MARCH 2020
Rent	7,64,800	7,30,800
Electricity, Power & Water	48,22,725	27,45,860
Loading/Unloading Charges	7,28,469	2,09,897
Fuel Charges	57,20,283	34,05,387
Total Rs.	1,20,36,277	70,91,944

Note No. 24 Administrative Expenses	31ST MARCH 2021	31ST MARCH 2020
Directors' Remuneration	28,40,000	27,73,935
Sitting Fee	81,000	81,000
Telephone, Fax & Internet	70,285	1,16,735
Packaging & Forwarding	2,88,396	59,573
Printing & Stationery	1,40,314	1,72,011
Postage & Telegram	51,174	7,961
Audit Fee	70,800	1,00,600
Legal & Professional Charges	16,26,631	8,58,969
Insurance Charges	2,41,838	2,50,252
AMC Charges	31,940	11,092
Testing Charges	17,700	81,886
Membership & Subscription	23,600	54,500
Rate, Fees & Taxes	4,55,139	95,912
Licence Fee	-	44,840

Tender Fee	6,400	7,360
Travelling & Conveyance	38,669	1,62,518
Repair & Maintenance -Plant & machinery	9,41,438	7,54,365
- General	9,44,848	6,25,735
Weightment Charges	22,990	41,419
Delivery Charges	2,51,49,182	85,06,516
Running & Maintenance	8,52,857	7,70,284
Advertisement & Publicity	1,32,479	8,58,869
Brokerage	4,93,933	1,91,513
Business Promotion	-	27,800
Sale Incentive	5,80,240	2,31,309
Marketing Expenses	10,19,672	27,31,982
Research & Development Expenses	6,99,022	-
Rebate & Discount	21,68,815	13,186
Charges on sale/purchase of shares	3,212	21,188
Tools & Dies	-	4,00,430
Stores & Spares	2,66,879	1,98,316
Diwali Expenses	1,08,790	7,741
Toll Charges	1,55,345	2,45,817
Car Rental	21,000	-
Bad Debts	944	119
Covid Expenses	11,000	-
Wood Fire Expenses	6,64,250	-
Miscellaneous Expenses	40,117	20,000
Total Rs.	4,02,60,898	2,05,25,733

NOTE : 25- NOTES ON ACCOUNTS & ACCOUNTING POLICIES

Forming part of Balance Sheet and Statement of Profit and Loss For the Year ended 31st March, 2021

A. SIGNIFICANT ACCOUNTING POLICIES :-

The following disclosure of accounting policies is made in pursuance of the recommendation of the Accounting standards Boards of the Institute of Chartered Accountants of India on 'Disclosure of Accounting Policies'.

a) System of Accounting :

The company has adopted Indian Accounting Standards (IndAS) as notified by the Ministry of Corporate Affairs with effect from 01st April 2020, with a transition date of 01st April 2019. The adoption of IndAs has been carried out in accordance with Ind AS 101, First Time Adoption of Indian Accounting Standards. Ind AS 101 requires that all Ind AS Standards and interpretations that are issued and effective for the First Ind AS Financial Statements for the year ended 31st March 2021. be applied retrospectively and consistently for all financial years presented .

b) Fixed Assets and Depreciation.:

Depreciation is provided on Written Down Value method assuming residual value as 5% over the useful lives of assets estimated by the Management. at the rates specified in Part C of Schedule II of the Companies Act 2013 on Pro rata basis and the Assets having the Value up to Rs 5000.00 have been depreciated at the rate of 100%.

c) Inflation :

Assets & Liabilities are recorded at historical cost to the company. These costs are not adjusted to reflect the changing value in the purchasing power of money.

d) Basis of Accounting.

The Accounts of the Company are prepared under the historical cost convention and in accordance with the requirements of the Companies Act, 2013 and accepted accounting standards. The accounts are prepared on accrual basis.

e) Valuation of Inventory

FIFO method of Stock valuation has been adopted by the company. Stock of raw material, stores & spares are valued at cost whereas stock of finished goods is valued at cost or net realisable value whichever is lower.

f) Events Occuring After the Valuation Date

Events occuring after the date of Balance Sheet, are considered up to date of finalisation of accounts, wherever material.

'g) Use Of Estimates

The preparation of the financial statements in conformity with INDAS requires management to make estimates and assumption that affect the reported balances of assets and liabilities and discloser relating to contingent liabilities as at the date of the financial statements and reported amounts of income and expenses during the period. Examples of such estimates include computation of percentage of completion which requires the company to estimates the efforts or cost expended to date as a proportion to date as a proportion of the total efforts or costs to be expended, provisions for doubtful debts, future obligation under employee retirement benefit plans, income taxes, post-sales customer support and the useful lives of fixed tangible assets and intangible assets.

Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

'h) Recognition Of Income & Expenditure

- (i) Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company, the significant risks and rewards of ownership have been transferred to the buyer and the revenue can be reliably measured in compliance with IND AS-18.
- (ii) Sales are recognised as & when the goods are supplied and net of GST. However rebate & discount is being seperately shown as other income.
- (iii) Expenses are accounted for on accrual basis and provision is made for all known losses and expenses.

'i) Employee's Benefits

The retirement benefits of the employees include Gratuity, Provident Fund & Contribution to the PF is provided on Accrual basis.No Provision has been made for Leave Encashment

'j) Cash Flow Statement

As per IND AS-7, an entity shall report cash flows from operating activities using either the direct method (whereby major classes of gross cash receipts and gross cash payments are disclosed) or the indirect method

(whereby profit or loss is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments, and items of income or expense associated with investing or financing cash flows), the Company chose to prepare the cash flow statements using the indirect method.

'k) Income Tax

Income tax is recognized in the Statement of income except to the extent that it relates to items recognized directly within equity or in other comprehensive income. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially-enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised

'l) Investments

During the current financial year company has sold investments. As per IND AS the Residual should be recognised at fair value and any change in the value should be recognised through FVTPL/FVOCI method. Hence the investments are recognised at fair value and effect of same has been dealt accordingly

B. NOTES ON ACCOUNTS :-

'1. Previous year figure have been re-grouped / re-arranged / re-caste wherever considered necessary, to suit the current year's layout as per the performa of Revised Schedule III of IND AS

'2. In the opinion of the Board, the current assets, loans & advances have a value on realisation in the ordinary course of business atleast equal to the amount at which they are stated in the balance sheet and that the provision for known liabilities are adequate and not in excess of amount reasonably necessary.

3. EPS CALCULATION

Particulars		2020-21	2019-20
Profit available for Equity Shareholders			
For Basic Earning:		3,730,517.60	3,468,012.13
No. of Weighted Average Equity Shares		10,005,582	8,405,024
For Diluted Earning:			
No. of Wighted Average of Diluted Equity Shares		10,005,582.00	8,405,024.00
Nominal Value of Equity Shares			
Earning Per Share (Rs.):			
Basic		0.37	0.41
Diluted		0.37	0.41

4. With reference to Employee Benefits, no provision has been made regarding Gratuity, Leave encashment & other retirement benefits & in absence of actuarial valuation there impact on financial statements are unascertainable.

a) Related Party disclosures are required under the Accounting standard (IAS-24) on "Related Party Disclosures" issued are given below:-

b) Relationship-

- (i) Holding Company – None
- (ii) Key Management Personnel (Managing / Whole Time Director) –
 Mr. Jasjot Singh
 Mr. Partek Singh
 Mr. Gursimran Singh
- (iii) Entities over which key management personnel / their Relatives are able to exercise significant influence
 - a) Punjab Biotechnology Park Limited
 Mr. Jasjot Singh- Common Director
 - c) M/s. Khanna Solvex
 Mr. Jasjot Singh- Partner in the partnership Firm
- (iv) Related Party Transaction

Description	2020-21	2019-20
Transaction during the year		
With Healthy Bioscience Private Limited		
Purchases within the year	34,00,610.00	2,51,55,631.10
Sale made during the year	0.00	0.00
Repayment made against purchases netted off sales	34,00,610.00	2,18,73,132.00
With Prism Medico & Pharmacy Pvt Ltd		
Purchases within the year	9,13,050.00	91,47,695.30
Sale made during the year	0.00	2,22,90,992.10
Repayment made against purchases	10,63,050.00	9,59,950.00
Collections Received	1,50,000.00	2,59,97,251.00
With Relatives-		
375000 Equity Shares Rs.10 each allotted to Jasjot Singh on 20.1.2020 at premium of Rs.5 each	--	56,25,000.00
600000 Equity shares Rs 10/- each allotted to Mr Jasjot Singh on 10.11.20 at premium of Rs 10 each	1,20,00,000.00	--
Rent paid to Healthy Biosciences Private Limited	2,12,400.00	94,400.00
Total (Rs.)	2,11,39,720.00	10,56,37,051.50

- 6) The Balance in the parties account whether debit or credit are subject to confirmation, reconciliation and adjustment.
- 7) Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advances).

	31st March, 2021	31st March, 2020
8) Contingent Liabilities not provided for :		
a. Bank Guarantees	Nil	Nil
b. Contingent Liabilities in respect of unassessed cases of Income Tax and Sales Tax.	Unascertained	Unascertained
c. Uncalled Liabilities as Shares partly paid	Nil	Nil
d. Claims not Acknowledged as debts	Nil	Nil
e. Letter of Credit(s)	Nil	Nil
9) CIF value of imports	Nil	Nil
10) Remittance in foreign Currency	Nil	Nil
11) Expenditure in Foreign Currency	Nil	Nil
12) Earning in Foreign Currency	Nil	Nil

13) In the opinion of Board of Directors, the Current Assets, Loan & advances shown in the Balance sheet have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated.

14) Auditors' Remuneration	31.03.2021	31.03.2020
As Statutory Audit Fee	70,800.00	59,000.00
Total.	70,800.00	59,000.00

15) Deferred Taxation

'In conformity with IND AS 12: Deferred tax Liability/ Asset is as follows:-

Particulars	Current Year	Previous Year
Difference on Account of Depreciation	7,36,245.87	13,24,829.09
Total Timing Difference	7,36,245.87	13,24,829.09
Tax Rate	26.00%	26.00%
'Deferred Tax Asset created on Timing Difference	1,91,423.93	3,44,455.26
Opening DTA/ DTL	12,73,605.26	9,29,150.00
Total Deferred Tax Asset	14,65,029.19	12,73,605.26

Deferred Tax Due to Depreciation :		
Timing Difference on Depreciation	Current Year	Previous Year
Depreciation as per Books of Accounts	43,68,129.61	35,12,793.49
Depreciation as per Income Tax Act	36,31,883.74	21,87,964.40
Timing Difference (Less Allowance By Income Tax)	7,36,245.87	13,24,829.09

16) **Details of Shareholders**

Details of Shareholders have been attached as per Annexure "B".

17) **Others**

'1) The company is engaged in business of selling Nil rated product i.e cattle feed , whose sales is done on FOR basis according to which the rate charged included the transportation cost per unit ascertained by company. The gst on such cost has not been ascertained by management due to nature of product being sold.

2) Migration of the company from SME to Main Board of NSE vide approval dated 05/05/2021 w.e.f. 07/05/2021.

18) 'Rounding of has been done to nearest 10

For AJOONI BIOTECH LIMITED

As per our separate report of even date attached

Jasjot Singh
(Managing Director)

Gursimran Singh
(Director)

For Harjeet Parvesh & Co.
Chartered Accountants

Gurmeet Singh
CFO
Date: 23/06/2021
Place: Mohali

Swati Vijan
CS

CA Konica Madan
M.No 547759

AJOONI BIOTECH LIMITED AS AT 31ST MARCH, 2021

TANGIBLE ASSETS

NOTE 01: FIXED ASSETS

BLOCK	Particulars	GROSS BLOCK				Salvage Value	DEPRECIATION				NET BLOCK	
		Balance as at 01-04-2020	Additions during the Year	Sales /Adjust ment During the year	Balance as at 31-03-2021		Up to 01-04-2020	During the Year	Transferr ed to Retained Earnings	Total as at 31-03-2021	as at 31-03-2021	As at 31-03-2020
A : CHANDIGARH												
BLOCK I	Land	1,11,72,255.00	0.00	0.00	1,11,72,255.00		0.00	0.00	0.00	0.00	1,11,72,255.00	1,11,72,255.00
BLOCK II	FURNITURE & FIXTURE Furniture & Fittings	73,134.00	0.00	0.00	73,134.00	3,657	29,809.86	11,216.62	0.00	41,026.48	32,107.52	43,324.14
BLOCK III	MOTOR VEHICLES - Car - Truck	11726195.99 0.00	0.00 24,99,120.00	0.00 0.00	1,17,26,195.99 24,99,120.00	5,86,310 1,24,956	71,44,906.55 0.00	14,30,938.17 2,78,742.15	0.00 0.00	85,75,844.72 2,78,742.15	31,50,351.27 22,20,377.85	45,81,289.44 0.00
BLOCK IV	PLANT & MACHINERY Plant & Machinery	1,01,51,374.00	1,70,62,371.00	0.00	27,213,745.00	1360687.00	52,71,710.28	26,27,713.14	0.00	7899423.42	1,93,14,321.58	48,79,663.72
BLOCK V	OFFICE EQUIPMENTS - Office Equipment	1,40,815.00	0.00	0.00	1,40,815.00	7,041	1,03,668.27	16742.76	0.00	120411.03	20403.97	37146.73
BLOCK VI	COMPUTER - Computer & Printers	38,599.00	46,400.00	0.00	84,999.00	4,250	36,999.32	2,776.76	0.00	39776.08	45222.92	1599.68
BLOCK VII	BUILDING UNDERCONST RUCTION *	0.00	15662041.00	0.00	15662041.00	783102.00	0.00	0.00	0.00	0.00	15662041.00	0.00
	TOTAL (A)	3,33,02,372.99	3,52,69,932.00	0.00	6,85,72,304.99	28,70,002.50	1,25,87,094.28	43,68,129.61	0.00	1,69,55,223.88	5,16,17,081.11	2,07,15,278.71
	PREVIOUS YEAR	1,92,93,955.99	1,40,08,417.00	0.00	3,33,02,372.99	11,06,505.90	90,74,300.79	35,12,793.49	0.00	1,25,87,094.28	2,07,15,278.71	1,02,19,655.41

Note: * No depreciation charged during year as Lab was under Construction

AJOONI BIOTECH LIMITED						
LIST OF SECURED BORROWINGS						
AS AT 31ST MARCH, 2021						
<i>Annexure A</i>						(Amount in Rs.)
YEAR	2021			2020		
PARTICULARS	Current	Non-Current	TOTAL (Rs.)	Current	Non-Current	TOTAL (Rs.)
	Period	Period		Period	Period	
Canara Bank - Car Loan	614,160.00	109,437.00	723,597.00	501,528.00	546,035.00	1,047,563.00
(Against hypothetication of Toyota Car (fortuner) car, Rate =8.80%						
ICICI Bank - Tata Motors-Mohali	0.00	0.00	0.00	64,605.00	0.00	64,605.00
ICICI Bank - Tata Motors-Rajasthan	0.00	0.00	0.00	29,053.00	0.00	29,053.00
Canara Bank - Car Loan (a/c 291)	167,820.00	360,587.00	528,407.00	95,603.00	495,817.00	591,420.00
(Against hypothetication of Bolero car, Rate =9.15% / Duration: 5 Years)						
Canara Bank - Car Loan (a/c 292)	167,832.00	360,588.00	528,420.00	95,461.00	496,101.00	591,562.00
(Against hypothetication of Balero car, Rate =9.15% / Duration: 5 Years)						
Canara Bank Term Loan-Machinery	3,570,003.00	10,689,951.00	14,259,954.00	0.00	0.00	0.00
(Against hypothetication of Plant & Machinery, Rate =10.15%p.a ,Duration 66 months)						
Cannara Bank Term Loan-a/c 2	2,633,328.00	438,896.00	3,072,224.00	0.00	0.00	0.00
(working capital demand Loan , Tenure -24 months/ against hypothetication of stock & book debts)						
Canara Bank Term Loan A/C 24	1,859,751.00	5,579,249.00	7,439,000.00	0.00	0.00	0.00
Against personal gurantee of MrJasjot Singh						

&Mr. Parteek Singh)						
Tenure 48 Months.Roi = 7.50%						
Hdfc Truck Loan	222,144.00	640,605.00	862,749.00	0.00	0.00	0.00
Against hypothetication of Vehicle ,tenure 60 months)						
TOTAL Rs.	9,235,038.00	18,179,313.00	27,414,351.00	786,250.00	1,537,953.00	2,324,203.00

BOOK-POST

If undelivered please return to:

AJOONI BIOTECH LIMITED

Registered Office: Plot No. D-118, Industrial Area, Phase VII, Mohali-160055

Works: Gaib Ki Pulli, Tehsil Khanna, Dist. Ludhiana, Punjab